

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
20 November 2021 :: Issue 633
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents

:: [Milestones - Perspectives](#)

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

Milestones - Perspectives

.....
.....

Washington Post

Nov 19, 2021The Health 202

Analysis

NIH director: 'Conspiracies are winning here'

Francis Collins wants online misinformation spreaders "brought to justice"

NIH Director Francis Collins has a stern message for the American public: The country has, what he called, an epidemic of misinformation and disinformation. And it's fueling a dangerous distrust in science.

"Conspiracies are winning here. Truth is losing. That's a really serious indictment of the way in which our society seems to be traveling," said Collins, who will soon [step down](#) as the National Institutes of Health director after serving in both Republican and Democratic administrations.

Collins made his most forceful comments yet against the pervasive spread of falsehoods online... He was defending his own colleague, Anthony Fauci, Biden's chief medical adviser, against the biggest onslaught of angry messages and threats he's received throughout the entire pandemic.

Those attacks stemmed in part from a viral and false claim that Fauci, who leads the National Institute of Allergy and Infectious Diseases, had funded a medical experiment that involved trapping beagles' heads in mesh cages filled with diseased sand flies. Fauci received so many messages — 3,600 phone calls in 36 hours — that his assistant quit answering the phone, Yasmeen and Beth Reinhard report in a [story out this morning...](#)

...The rapid-fire spread of misinformation has altered public opinion of the pandemic and coronavirus vaccines. Some 6 in 10 Americans say they either believe the government is exaggerating the number of deaths from the virus or aren't sure. **Nearly 1 in 4 Americans believe covid-19 shots contain microchips or don't know if the claim is true,** according to a recent [Kaiser Family Foundation survey.](#)

"Truth is supposed to be truth," Collins said, "and the fact that your truth would be so heavily modified by your social circle or where you get your news tells you we're in real trouble." **He said he worries about a society where "somebody's Facebook post carries as much weight as a statement from the director of the CDC about what is the truth of a public health crisis."**

He sees two ways of attempting to curb the spread of misinformation, though admits he's unsure how successful either has been.

:: The first: Identify those who are purposefully spreading false information online and bring them to justice.

:: The second: Find a better way to counter false claims with real information. He didn't specify what exactly either one would entail...

.....

.....

WHASS2: Special session of the World Health Assembly referred to in decision WHA74(16)

29 November – 1 December 2021

Geneva, Switzerland | Virtual event

Draft provisional agenda [dated 12 Oct 2021]: [SSA2/1 \(draft\)](#)

The World Health Assembly (WHA) will gather for a special session 29 November to 1 December to consider developing a **WHO convention, agreement, or other international instrument on pandemic preparedness and response**.

The WHA normally meets each May. This special session (the second in the history of the WHO) was called for in a decision adopted by the Member States at the Seventy-fourth World Health Assembly: [Decision WHA74\(16\)](#).

During the session, the Member States will consider the following single substantive agenda item: *Consideration of the benefits of developing a WHO convention, agreement or other international instrument on pandemic preparedness and response with a view towards the establishment of an intergovernmental process to draft and negotiate such a convention, agreement or other international instrument on pandemic preparedness and response, taking into account the report of the Working Group on Strengthening WHO Preparedness and Response to Health Emergencies.*

The Working Group on Strengthening WHO Preparedness and Response to Health Emergencies, established after the WHA74, has met on four occasions and considered findings from several bodies in preparing its report. The sessions will be public and webcast on this page and other WHO channels.

ZERO DRAFT Report of the Member States Working Group on Strengthening WHO Preparedness for and Response to Health Emergencies to the special session of the World Health Assembly

FOURTH MEETING OF THE WORKING GROUP ON STRENGTHENING WHO PREPAREDNESS AND RESPONSE TO HEALTH EMERGENCIES A/WGPR/4/3

Provisional agenda item 2

28 October 2021 :: 15 pages

.....

.....

World Organisation for Animal Health (OIE) [to 20 Nov 2021]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

The World Organisation for Animal Health (OIE) calls for increased surveillance of avian influenza as outbreaks in poultry and wild birds intensify

Press Release 19 November 2021

Various subtypes of high pathogenicity avian influenza have been reported by more than 40 countries over the last six months.

During the high-risk period of this disease October to April, countries need to scale up surveillance efforts, implement strict biosecurity measures and ensure a timely reporting of outbreaks to curb its spread.

Paris, 19 November 2021 – Since 1 May 2021, outbreaks of high pathogenicity avian influenza (HPAI) have been confirmed in 41 countries from different regions in poultry and wild birds. Currently present in Africa, Asia and Europe, the disease is a threat to economic stability, food security and livelihoods. Commonly known as bird flu, avian influenza is a very contagious disease which affects several species of poultry, as well as pet birds and wild birds, and occasionally, humans. This complex disease is caused by viruses divided in multiple subtypes whose genetic characteristics rapidly evolve. Over recent years, numerous subtypes of the HPAI viruses have been circulating in diverse bird populations on a large geographical scale. In particular in 2021, an unprecedented genetic variability of subtypes has been reported in birds, thus creating an epidemiologically challenging landscape. H5N1, H5N3, H5N4, H5N5, H5N6 or H5N8 are the subtypes currently circulating in poultry and wild bird populations across the world...

Because of the disease impacts on the livelihoods of poultry farmers and on international trade, as well as the risks of transmission to humans, the animal health sector must implement strict biosecurity measures in farms, in commerce and in live bird markets to prevent it from spreading. For instance, isolating infected birds from healthy ones and cleaning and disinfecting poultry premises is highly recommended. Proper planning and the implementation of surveillance programmes in wild birds, as well as, avoiding direct or indirect contact between domestic and wild birds is equally critical in mitigating outbreaks in domestic poultry and preventing the introduction of the virus into flocks. Thus, the OIE urges countries to maintain their surveillance efforts and to continue timely reporting of avian influenza outbreaks in both poultry and non-poultry species including wild birds.

.....
.....

[A supply gap of more than 1 billion autodisable syringes could impact COVID-19 immunization efforts in 100 countries](#)

Global convening of syringe manufacturers and multilateral organizations held to help bolster supply.

Seattle, Washington, November 17, 2021—New PATH modeling estimates a global market supply gap of 1.2 billion autodisable (AD) syringe safe-injection devices for COVID-19 vaccine delivery. This supply gap risks becoming a bottleneck that could threaten the timely delivery of vaccines in half of the countries on Earth.

On November 11, PATH and the United Nations Children’s Fund (UNICEF) held a **Global COVID-19 Vaccine Syringe Industry Convening bringing together more than two dozen of the world’s leading syringe manufacturers and multilateral organizations to facilitate increased transparency around the AD syringe market** to help bolster supply for COVID-19 vaccines as well as routine immunization. Manufacturers confirmed critical global AD syringe supply challenges from the end of 2021 through mid-2022, despite tripling their production and efforts by multilateral organizations to secure additional AD syringes for low- and middle-income countries that need them.

The projected spike in demand for syringes for COVID-19 vaccines, estimated to total more than 4 billion from the end of 2021 to mid-2022, is due to the anticipated surge in COVID-19 vaccine dose deliveries to countries coming through COVAX, large donations from governments, and bilateral deals. Based on the global supply and demand data, the [PATH modeling](#) estimates a global gap of 1.2 billion AD syringes.

Risks to syringe supply such as country export restrictions, shipping delays, new manufacturing lines failing to receive World Health Organization (WHO) prequalification, or delays in completing planned manufacturing expansions could widen the cumulative gap to more than 2 billion during this period. Booster doses could create additional demand pressures on the market.

“Our gap analysis is designed to demystify the market and spur efforts in both public and private sectors to prioritize equitable access to COVID-19 vaccines and syringes in every country as well as to safeguard syringe supplies for essential vaccines for children,” said Tara Herrick, Senior Market Analytics Officer, PATH. “While these future projections are not set in stone, collectively our actions could help curtail the size of future gaps to help reach the global COVID-19 vaccination target of 70 percent by 2022.”

Immunization is done exclusively with AD syringes in nearly 70 countries, and 30 countries use them for some immunizations. Since 1999, the WHO, UNICEF, and the United Nations Population Fund have recommended exclusive use of AD syringes globally for immunization as they “present the lowest risk of person-to-person transmission of blood-borne pathogens such as hepatitis B or HIV” because AD syringe needles cannot be removed or reused...

.....
.....

[Pfizer and The Medicines Patent Pool \(MPP\) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries](#)

Tuesday, November 16, 2021

:: Agreement builds on Pfizer’s comprehensive strategy to work toward **equitable access to COVID-19 vaccines and treatments for all people, particularly those living in the poorest parts of the world**

:: Agreement will enable qualified sub-licensees to supply countries comprising approximately 53% of the world’s population

:: **Interim data from the Phase 2/3 EPIC-HR study demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death compared to placebo** in non-hospitalized high-risk adults with COVID-19 within three days of symptom onset with similar results seen within five days of symptom onset

NEW YORK & GENEVA--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and the Medicines Patent Pool (MPP), a United Nations-backed public health organization working to increase access to life-saving medicines for low- and middle-income countries, today announced the signing of a voluntary license agreement for Pfizer’s COVID-19 oral antiviral treatment candidate PF-07321332, which is administered in combination with low dose ritonavir (PF-07321332; ritonavir). The agreement will enable MPP to facilitate additional production and distribution of the investigational antiviral, pending regulatory authorization or approval, by granting sub-licenses to qualified generic medicine manufacturers, with the goal of facilitating greater access to the global population.

Under the terms of the head license agreement between Pfizer and MPP, **qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply PF-07321332 in combination with ritonavir to 95 countries, covering up to approximately 53% of the world’s population.** This includes all low- and lower-middle-income countries and some

upper-middle-income countries in Sub-Saharan Africa as well as countries that have transitioned from lower-middle to upper-middle-income status in the past five years. **Pfizer will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.**

"Pfizer remains committed to bringing forth scientific breakthroughs to help end this pandemic for all people. We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections, decreasing the strain on our healthcare systems and saving lives," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. "We must work to ensure that all people – regardless of where they live or their circumstances – have access to these breakthroughs, and we are pleased to be able to work with MPP to further our commitment to equity."

"This license is so important because, if authorized or approved, **this oral drug is particularly well-suited for low- and middle-income countries** and could play a critical role in saving lives, contributing to global efforts to fight the current pandemic," said Charles Gore, Executive Director of MPP. "PF-07321332 is to be taken together with ritonavir, an HIV medicine we know well, as we have had a license on it for many years, and we will be working with generic companies to ensure there is enough supply for both COVID-19 and HIV."

"Unitaid, a global health agency, created MPP ten years ago for this exact purpose – to secure licenses that enable and accelerate access to affordable quality treatments for people in resource-limited settings," said Dr Philippe Duneton, Executive Director, Unitaid. "During a pandemic, saving time means saving lives. This agreement could help us to reach more people more quickly as soon as the medicine is approved and, when coupled with increased access to testing, bring benefits to millions."

.....
.....

[Members to continue discussion on a common COVID-19 IP response up until MC12](#)

World Trade Organisation

18 November 2021

At a formal meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 18 November, WTO members agreed to keep actively engaging up until the WTO's 12th Ministerial Conference (MC12) in order to find a common intellectual property (IP) response to COVID-19. The chair of the Council, Ambassador Dagfinn Sørli of Norway, said he will make sure no stone is left unturned to explore all available options towards a consensus-based outcome at the **Ministerial Conference taking place from 30 November to 3 December.**

Members adopted the oral status report that will be submitted by the chair of the TRIPS Council to the General Council scheduled for 22-23 November. The text provides a factual overview of discussions held at the TRIPS Council since October 2020, both on the proposal by India and South Africa ([IP/C/W/669/Rev.1](#)) requesting a waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 and the proposal by the European Union ([IP/C/W/681](#)) for a draft General Council declaration on the TRIPS Agreement and Public Health in the circumstances of a pandemic.

While the report indicates that delegations remain committed to the common goal of providing timely and secure access to high-quality, safe, efficacious and affordable vaccines and medicines for all, it also acknowledges that differences remain on significant questions.

On the waiver request proposal, the report indicates that disagreement persists on the fundamental question of whether a waiver is the appropriate and most effective way to address the shortage and inequitable distribution of, and access to, vaccines and other COVID-19-related products. On the EU proposal, the report notes that disagreement persists on the fundamental question of whether this initiative is the appropriate and most effective way to address the shortage and inequitable distribution of, and access to, vaccines and other COVID-19-related products.

This means that the TRIPS Council will remain in session beyond the General Council and potentially all the way to the Ministerial Conference. Therefore, the Council will continue to provide a forum for delegations to provide transparency on their ongoing talks and to adopt any elements or solutions they may have found so that they can be recommended to ministers before MC12 starts.

Ambassador Sørli encouraged members to remain seriously engaged, flexible and focused on an outcome, which in his view still remains within reach. The role of IP in the context of the pandemic has become the centre of attention in the run-up to MC12, and a pragmatic and tangible outcome of these discussions would be a strong and positive signal to the Ministerial Conference and the global community as a whole, he said...

.....
.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 19 Nov 2021

Confirmed cases :: 255 324 963 [251 788 329 week ago]

Confirmed deaths :: 5 127 696 5 077 907 week ago]

Vaccine doses administered: 7 370 902 499 [7 160 396 495 week ago]

.....

[Weekly epidemiological update on COVID-19 - 16 November 2021](#)

WHO


Overview

During the week 8 to 14 November 2021, the increasing trend in new global weekly cases continued, with over 3.3 million new cases reported – a 6% increase as compared to the previous week. The Region of the Americas, the European and the Western Pacific Regions all reported increases in new weekly cases as compared to the previous week, while all other regions reported stable or declining

trends. Similarly, the European Region reported a 5% increase in new deaths, while the other regions reported stable or declining trends. Globally, just under 50 000 new deaths were reported, similar to the previous week. As of 14 November, over 252 million confirmed cases and over 5 million deaths have been reported.

In this edition, we provide updates on the geographic distribution of SARS-CoV-2 Variants of Concern (VOCs), and summarise phenotypic characteristics (transmissibility, disease severity, risk of reinfection, and impacts on diagnostics and vaccine performance) of VOCs based on available studies.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 14 November 2021**



**See [Annex 3: Data, table, and figure notes](#)



WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected

No new digest content identified



[Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 11 November 2021](#)












For 24 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[Full scale view available at title link above]

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.	 BioNTech Manufacturing GmbH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA USFDA	Nucleoside modified mRNA	✓	✓	✓	Finalized: Additional sites: – Baxter Oncology GmbH Germany (DP) – Novartis Switzerland – Mibe (Dermapharm) Germany (DP) – Delpharm, Saint-Remy FRANCE (DP) – Shelf life extension: 09 months at -70 to -90°C – Sanofi-Aventis Deutschland GmbH Germany Diluent suppliers: – Pfizer Perth, Australia/Fresenius Kabi, USA	31/12/2020 30/06/2021 08/07/2021 16/07/2021 17/09/2021 20/09/2021 06/10/2021 18/06/2021
2.		AZD1222 Vaxzevria	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021
3.	 AstraZeneca, AB	AZD1222 Vaxzevria	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized: Additional sites: – SK-Catalent – Wuxi (DS) – Chemo Spain – Amylin Ohio US (DP)	16 April 2021 30 April 2021 04 June 2021 23 July 2021 15 Feb 2021
4.		AZD1222 Vaxzevria	Japan MHLW/PMDA		✓	✓	✓	Finalized Additional sites: Nipro Pharma Corporation Ise, Japan	09 July 2021 11 October
5.		AZD1222 Vaxzevria	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized Additional site: Siam Bioscience Co., Ltd Thailand	09 July 2021 11 October 2021
6.					✓	✓	✓		
7.	 Serum Institute of India Pvt. Ltd	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized DS and DP Manjari Bk Pune	15 Feb 2021 12 Nov 2021
8.	 Janssen-Cilag International NV	Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US+NL sites) Additional sites: – Aspen RSA (DP) – Catalent Agnani Italy (DP) – Merck, Durham, UK (DS) – Future submission – Merck, West Point/PA (DP)	12 March 2021 -25 June 2021 - 02 July 2021 - As submitted - 05 November 2021

WHO PREQUALIFICATION  World Health Organization

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
9.	 Moderna Biotech	mRNA-1273	USFDA	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP) mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized Finalized ModernaTx, Norwood (DS) – Catalent Indiana, LLC (DP) – Lonza Biologics, Inc. Portsmouth, USA (DS) – Baxter, Bloomington, USA (DP)	30 April 2021 06 August 2021
10.	 Sinopharm / BIBP ¹ Beijing Institute of Biological Products Co., Ltd. (BIBP)	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA		✓	✓	✓	Finalized 2 and 5 dose presentation (new manufacturing site)	07 May 2021 TBC after ongoing inspection
11.	 Sinovac Life Sciences Co., Ltd. Sinovac Life Sciences Co., Ltd.	COVID-19 Vaccine (Vero Cell), Inactivated/Coronovac™	NMPA	Inactivated, produced in Vero cells	✓	✓		Finalized 2 dose presentation	01 June 2021 30 September 2021
12.	 THE GAMALEYA NATIONAL CENTER	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	Process restarted, awaiting completion of rolling submission and CAPAs to last inspection-	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
13.	 Bharat Biotech, India	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/COVAXIN	DCGI	Whole-Virion Inactivated Vero Cell	✓	✓	✓	Finalized	03 November 2021
14.	 Sinopharm / WIBP ²	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓		Rolling data started 23 July 2021	Ongoing To be confirmed
15.	 康希诺生物 Cansinbio	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓		Rolling data started 09 August 2021	Ongoing; inspection ongoing TBC
16.	 NOVAVAX	NVX-CoV2373/Covovax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓		Rolling data started 19 August 2021	Ongoing TBC
17.	 SANOFI	CoV2 preS dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓			Rolling data started 30 July 2021	Ongoing TBC
18.	 Serum Institute of India Pvt. Ltd	NVX-CoV2373/Covovax	DCGI	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓			Rolling data started 21 September 2021	Ongoing TBC
19.	Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	✓		Rolling data started 20 September	Screened and communicated gaps. Data awaited
20.	 LIFECVAX	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: C19CoV/CV07050102	EMA	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓		Application withdrawn by manufacturer		
21.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	✓		Presubmission planned		

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
22.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
23.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
24.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co-Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant; 4. Risk-benefit decision 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.



COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca

Press Releases

[New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention](#)

18 November 2021

[Two billion doses of AstraZeneca's COVID-19 vaccine supplied to countries across the world less than 12 months after first approval](#)

16 November 2021

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - [Website not responding at inquiry; receiving 403-Forbidden]

CanSinoBIO

News - [Website not responding at inquiry]

Clover Biopharmaceuticals - China

News

Nov 18, 2021

[Clover and CEPI Expand Partnership for COVID-19 Vaccine Candidate to Include Evaluation as a Booster](#)

:: CEPI commits up to an additional US\$36.9 million for a total investment of up to \$397.4 million to support the development of Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum)

:: CEPI funding supports development of SCB-2019 (CpG 1018/Alum) for primary vaccination across all age groups (pediatric, adolescent, adults, and elderly) and development as a potential booster

Curevac [Bayer Ag – Germany]

News

November 18, 2021

[CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine](#)

Gamaleya National Center

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China

Home - No new digest announcements identified

Janssen/JNJ

Press Releases - No new digest announcements identified

Moderna

Press Releases

November 19, 2021

[**U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna's COVID-19 Vaccine**](#)

November 19, 2021

[**Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older**](#)

November 18, 2021

[**Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus \(RSV\) Vaccine**](#)

November 17, 2021

[**Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years**](#)

November 16, 2021

[**Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries**](#)

November 15, 2021

[**Health Canada Authorizes Booster Dose of Moderna's COVID-19 Vaccine in Individuals 18 Years of Age and Older**](#)

Novavax

Press Releases

[**Novavax Statement on Publication of Positive Results from First Study of Co-administered COVID-19 and Influenza Vaccines**](#) Nov 18, 2021

[**Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization**](#) Nov 17, 2021

[**Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines**](#) Nov 17, 2021

[Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373](#) Nov 15, 2021

Pfizer

[Recent Press Releases](#)

11.19.2021

[Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older](#)

11.16.2021

[Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate](#)

11.16.2021

[Pfizer and The Medicines Patent Pool \(MPP\) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries](#)

[See COVID above for detail]

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified

Serum Institute of India

[NEWS & ANNOUNCEMENTS](#)

Wednesday, November 17, 2021

[Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines](#)

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified

Sinovac

[Press Releases](#) - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

[Home](#) - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

[Press releases for media](#)

17 November 2021 **[GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment](#)**

Merck

[News releases](#) - No new digest announcements identified

Novartis

News - No new digest announcements identified

SK Biosciences

Press releases

[SK bioscience Submits Biologics License Application to the KMFDS for Novavax Covid-19 Vaccine Candidate](#)

The first submission of a protein-based COVID-19 vaccine candidate in Korea...
2021. 11. 15

Valneva

Press Releases

November 15, 2021

[Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting](#)

.....
.....

[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 20 Nov 2021](#)

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]



.....
.....

[IMF-WHO Vaccine Supply Forecast Dashboard](#)

Updated on 19 November 2021

Many countries are not on track to meet the 40% vaccine coverage target. To make progress towards this target, we must identify: (1) Where and in which countries are the gaps?, and (2) How can gaps be addressed?

The IMF-WHO COVID-19 Vaccine Supply Forecast Dashboard estimates expected month vaccine supply until the end of 2021 by country, product and channel. The tracker builds on the work of the IMF Staff Discussion Note – A Proposal to End the COVID-19 Pandemic (Agarwal and Gopinath, 2021).

3. Gap to 40% and Excess Doses by Country Group

End-Dec End-Nov End-Oct End-Sep

Baseline Scenario Low Supply Scenario High Supply Scenario

Gap to 40% expected coverage

	World	AMC91	High Income Countries	UMIC (excl. China)
Number of countries not on track to reach 40% coverage	73	60	0	13
Number of doses (mn.) needed for all countries to reach 40% coverage	563	539	0	24

Excess doses above 100% expected coverage

Number of countries on track to reach above 100% coverage	48	3	39	5
Number of excess doses (mn.) expected above 100% coverage	637	0	474	77

Other

Total number of countries	196	91	60	43
Total population (mn.)	7,868	2,587	1,236	1,208
Total number of doses supplied (mn.)	11,025	1,779	2,910	1,758
Total effective coverage (%)	70	34	118	73

Source: IMF & WHO Staff calculations. Effective vaccine supply = doses/2/population. J&J and CanSino volumes have been doubled for comparability with the other two dose candidates in the portfolio.



Duke – Launch and Scale Speedometer **[The Race for Global COVID-19 Vaccine Equity](#)**

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution *[accessed 24 July 2021]*

[See our COVID Vaccine Purchases research](#)



[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.
 Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
 Top 10 Donating Countries



Data updated on November 12th 2021.







Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 20 Nov 2021]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

20 Nov 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 255M total confirmed cases; 5.1M total confirmed deaths

Global vaccines administered: 7.62B

Number of Countries: 30 [30 week ago]

COVAX Allocations Round 4-9 (Number of Doses): 220M

COVAX Delivered (Number of Doses): 160M [140M week ago]
Other Delivered (Number of Doses): 260M [250M week ago]
Total Delivered (Number of Doses): 410M [390M week ago]
Total Administered (Number of Doses): 330M [310M week ago]

.....
.....


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **20 Nov 2021**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



Doses ?

● Required Doses (end 2021)

6.2B doses

(40% of total population)

● Required Doses (mid 2022)

10.9B doses

(70% of total population)

● Secured Vaccines / Expected Vaccine Supply


18.2B doses

● Delivered Doses

8.5B doses

● Doses Administered

7.5B doses




Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 20 Nov 2021]

:: [53.1%](#) of the world population has received at least one dose of a COVID-19 vaccine.

:: [7.66 billion doses](#) have been administered globally, and [27.25 million](#) are now administered each day.

:: Only [5%](#) of people in low-income countries have received at least one dose.




Share of the population fully vaccinated against COVID-19, Nov 19, 2021

Our World
in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 20 November 2021, 11:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

▶ Dec 13, 2020 ○ Nov 19, 2021

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

FDA

Press Announcements

[November 19, 2021 - Coronavirus \(COVID-19\) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters](#)

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals 18 years of age and older after completion of primary vaccination with any FDA-authorized or approved COVID-19 vaccine. The Centers for Disease Control and Prevention's (CDC) [Advisory Committee on Immunization Practices](#) will meet later today to discuss further clinical recommendations.

"Throughout the course of the COVID-19 pandemic, the FDA has worked to make timely public health decisions as the pandemic evolves. COVID-19 vaccines have proven to be the best and highly effective defense against COVID-19. Authorizing the use of a single booster dose of either the Moderna or Pfizer-BioNTech COVID-19 vaccine for individuals 18 years of age and older helps to provide continued protection against COVID-19, including the serious consequences that can occur, such as hospitalization and death," said Acting FDA Commissioner Janet Woodcock, M.D...

..."The FDA has determined that the currently available data support expanding the eligibility of a single booster dose of the Moderna and Pfizer-BioNTech COVID-19 vaccines to individuals 18 years of age and older," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "Streamlining the eligibility criteria and making booster doses available to all individuals 18 years of age and older will also help to eliminate confusion about who may receive a booster dose and ensure booster doses are available to all who may need one."...

[November 16, 2021 - Coronavirus \(COVID-19\) Update: November 16, 2021](#)

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

No meetings on [calendar](#)

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

[Statement of President Joe Biden on Pfizer's COVID-19 Antiviral Treatment](#)

November 18, 2021 • Statements and Releases

U.S. Department of State

<https://www.state.gov/coronavirus/releases/>

Media Note

[Department of State Announces COVID-19 Private Sector Engagement and Partnership Fund Awardees](#)

November 12, 2021

.....

.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases •

[News: EMA issues advice on use of Lagevrio \(molnupiravir\) for the treatment of COVID-19 \(new\)](#)

CHMP, Last updated: 19/11/2021

[News: EMA starts review of Paxlovid for treating patients with COVID-19 \(new\)](#)

CHMP, Last updated: 19/11/2021

[News: European Antibiotic Awareness Day: Fighting the silent pandemic \(new\)](#)

Last updated: 18/11/2021

[News: EMA receives application for marketing authorisation for Xevudy \(sotrovimab\) for treating patients with COVID-19 \(new\)](#)

CHMP, PDCO, PRAC, Last updated: 18/11/2021

[News: EMA receives application for conditional marketing authorisation of Novavax's COVID-19 vaccine, Nuvaxovid \(new\)](#)

CHMP, Last updated: 17/11/2021

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

Publication

[Assessment of electronic health records for infectious disease surveillance](#)

Technical report - 19 Nov 2021

News

[Reported decrease in antibiotic consumption across EU/EEA during COVID-19 pandemic](#)

Press release - 18 Nov 2021

Publication

[Antimicrobial consumption in the EU/EEA \(ESAC-Net\) - Annual Epidemiological Report for 2020](#)

Surveillance report - 18 Nov 2021

.....



European Centre for Disease Prevention and Control

COVID-19 Vaccine Tracker

Cumulative uptake of at least one dose in the total population in EU/EEA	Cumulative uptake of full vaccination in the total population in EU/EEA
69.9%	65.5%

Accessed 20 Nov 2021

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....


European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

No new digest content identified.

.....
.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment




Africa CDC Vaccine Dashboard

Africa Vaccinated

Vaccine Administered (Total)	(59.42% of supply)
Partially Vaccinated	(9.52% of population)
Vaccination Completed	(6.48% of population)

Total of Supply Administered



Vaccines received from COVAX	Vaccines received bilaterally	Vaccines received from AVATT
50	50	36
Countries	Countries	Countries

Accesses 20 Nov 2021. Full scale, interactive dashboard available at: <https://africacdc.org/covid-19-vaccination/>

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[A study in Belarus on Sputnik V shows high safety profile and 96.3% efficacy against COVID after vaccination of over 1.2 million people](#)

Press release, 17.11.2021

.....
.....



India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
20 November 2021, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)



COVID-19 Vaccination
as on : 20 November
2021, 08:00 IST
(GMT+5:30)



Government of India – Press Information Bureau

[Latest Press Releases](#)

[COVID-19 Vaccination Update - Day 309](#)

:: India’s cumulative vaccination coverage crosses 116 crore landmark milestone

:: More than 60 lakh Vaccine doses administered today till 7 pm

Posted On: 20 NOV 2021

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[China helps international vaccine drive](#)

2021-11-19

...During an online discussion attended by foreign ministers and leaders of international organizations on Nov 11, China's ambassador to the United States, Qin Gang, said China has provided more than 1.7 billion doses of vaccines to more than 100 countries. By the end of the year, the country is aiming to provide a total of 2 billion doses, he said.

Qin said China has also supplied over 70 million vaccine doses and donated \$100 million to the global vaccine-sharing platform COVAX.

More than 99 percent of vaccines provided by China for global use have been shipped to developing countries...

[Shanghai to launch COVID-19 vaccination for children aged 3 to 5](#)

2021-11-19

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

[Polio this week as of 17 November 2021](#)

:: In Afghanistan, advance notification was received of two new wild polioviruses type 1 (WPV1) cases in the country. These cases will officially be reflected in next week's data. The cases had onset of paralysis on 20 and 29 October 2021, from Kunduz province.

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

– **Nigeria:** six cVDPV2 cases and 26 cVDPV2 positive environmental samples

.....
.....

WHO/OCHA Emergencies

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

[Afghanistan crisis](#) [*Last apparent update: 5 Aug 2021*]

[Crisis in Northern Ethiopia](#) [*Last apparent update: 18 Oct 2021*]

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) [*Last apparent update: 17 Aug 2021*]

[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#) [*Last apparent update: 17 Aug 2021*]

[Coronavirus disease \(COVID-19\) pandemic](#) [*See COVID above*]

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[*Last apparent update: 17 Aug 2021*]

[Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020](#)

[*Last apparent update: 17 Aug 2021*]

[Ebola outbreak, Democratic Republic of the Congo, 2018](#) [Last apparent update: 24 July 2018]

[Yemen crisis](#) [Last apparent update: 12 February 2021]

[Syria crisis](#) [Last apparent update: 18 June 2021]

[Somalia crisis](#) [Last apparent update: 24 March 2018]

[Nigeria crisis](#) [Last apparent update: 1 Oct 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) [Last apparent update: 17 Aug 2021]

[Zika virus disease outbreak, 2015-2016](#) [Last apparent update: 24 Jan 2020]

[Ebola outbreak: West Africa, 2014-2016](#) [Last apparent update: 17 Aug 2021]

[Iraq crisis](#) [Last apparent update: 9 Jan 2008]

[South Sudan crisis](#) [Last apparent update: 23 Sep 2020]

[Avian influenza A \(H7N9\) virus outbreak](#) [Last apparent update: 13 September 2021]

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) [Last apparent update: 8 July 2019]

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) [Last apparent update: 10 Aug 2010]

.....

[UN OCHA – Current Emergencies](#)

Current Corporate Emergencies

Afghanistan

No new updates identified

Northern Ethiopia

[Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 18 Nov 2021](#)

HIGHLIGHTS

- About 8 million people in northern Ethiopia are targeted to receive humanitarian assistance until the end of the year. In Amhara, tens of thousands of people are reportedly displaced from South Wello, North Wello & Wag Hemra zones to Debre Berhan City in North Shewa Zone because of active fighting
- More than 16,000 displaced people were evicted from primary schools in Tigray since beginning of November.
- No humanitarian supplies, including cash, have arrived in Tigray for almost a month. Fuel has not arrived since beginning of August.
- Humanitarian partners in Afar and Amhara are scaling up the response in accessible areas, assisting more than 150,000 people with food in both regions during the reporting period.

.....
.....

WHO & Regional Offices [to 20 Nov 2021]

<https://www.who.int/>

Selected News, Statements

17 November 2021

News release

[Global leaders call for cervical cancer elimination on Day of Action](#)

17 November 2021

Departmental news

[Global individual patient data platform for drug-resistant tuberculosis treatment](#)

16 November 2021

Departmental news

[Leadership in Emergencies: Building competencies for effective leadership in all-hazards emergency response](#)

16 November 2021

Joint News Release

[UN Agencies Back Bold Plan To Ensure Every Child In Need Gets A Regular Healthy Meal In School By 2030](#)

16 November 2021

Departmental news

[No research about us without us: why research capacity strengthening is essential to health for all](#)

16 November 2021

Departmental news

[WHO releases new toolkit to support quality HIV testing services](#)

15 November 2021

Departmental news

[WHO and Bayer renew longstanding collaboration to accelerate control and elimination of neglected tropical diseases](#)

15 November 2021

Departmental news

[New reduced costs of dual HIV/syphilis rapid tests to accelerate progress toward elimination of mother-to-child transmission of HIV and syphilis](#)

13 November 2021

Departmental news

[WHO Global Evidence-to-Policy \(E2P\) Summit: Evidence as a catalyst for policy and societal change.](#)

.....

[Weekly Epidemiological Record, Vol. 96, No. 46, pp. 557–568 19 November 2021](#)

557 Elimination of human onchocerciasis: progress report, 2020

567 Monthly report on dracunculiasis cases, January-September 2021

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: Diabetes prevention, care challenges in Africa 17 November 2021

:: On the frontlines of diabetes fight in Senegal 15 November 2021

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

:: Knowledge, funding and action needed to keep antimicrobials working 18-11-2021

:: "Consult your doctor about antibiotics first": using digital marketing to tackle antimicrobial resistance in Ukraine 18-11-2021

:: One Health and the fight against antimicrobial resistance in Italy 18-11-2021

WHO Eastern Mediterranean Region EMRO

:: Regulating the use of antimicrobials in a fragile context 17 November 2021

:: Building capacity of frontline health care workforce on latest COVID-19 clinical management practices priority for WHO 17 November 2021

:: COVID-19 vaccines delivered to Islamic Republic of Iran to increase protection of Afghan refugees 16 November 2021

:: Medical supplies airlifted to Afghanistan save lives 14 November 2021

WHO Western Pacific Region

No new digest content identified

.....

New WHO Publications [Selected]

<https://www.who.int/publications/i>

Selected Titles

17 November 2021

[Strategic toolkit for assessing risks: a comprehensive toolkit for all-hazards health emergency risk assessment](#)

17 November 2021

[Generating Evidence for Artificial Intelligence Based Medical Devices: A Framework for Training Validation...](#)

[Download \(1.4 MB\)](#)

Overview

This first-of-its-kind publication from the WHO is a framework targeted at developers and researchers of AI-based software as a medical device, as well as policy-makers and implementers. It is intended to guide those seeking to understand the evidence generation requirements from development to post-market surveillance of these devices.

The publication uses cervical cancer screening as a use-case to support the goals of the WHO strategy on cervical cancer elimination and set the foundations for WHO to be able to usher in new and emerging technologies in cancer screening and beyond.

To allow acceleration in the global effort in cancer screening and clinical decision support, WHO will begin to facilitate building the enabling environments so that the benefits of innovative technologies reaches all populations and use-cases of high disease burden globally.

16 November 2021

[Guidance on operational microplanning for COVID-19 vaccination](#)

Overview

<https://apps.who.int/iris/rest/bitstreams/1390309/retrieve>

This publication is a companion document to the NDVP [National Deployment and Vaccination Plans](#) guidance, which provides a framework for countries to develop their national strategies. As countries face challenges with erratic vaccine supplies, use of multiple vaccine products with different characteristics, and the size of populations and their diversity, this document provides operational guidance and information to support planners and immunization programme managers at the national and sub-national levels on microplanning for COVID-19 vaccination implementation.

This publication was developed through a consultative process that included all six WHO Regional Offices, as well as partner agencies supporting the rollout of COVID-19 vaccination.

16 November 2021

[Hepatitis B Control: Country Profile 2020](#)

15 November 2021

[Case study: development of the national road map for enhancing health sector engagement/contribution...](#)

15 November 2021

[Optimizing HIV testing algorithms: a generic verification protocol for selecting appropriate HIV serology...](#)

14 November 2021

[Pandemic Influenza Preparedness Framework: 18-month progress report, 1 January 2020–30 June 2021](#)

.....
.....

CDC/ACIP [U.S.] [to 20 Nov 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements [Selected]

[CDC Expands Eligibility for COVID-19 Booster Shots to All Adults](#)

Friday, November 19, 2021

[See U.S. COVID Response above for detail]

[ACIP Meetings](#)

:: [Agenda – November 19, 2021 pdf](#) [COVID Boosters/Adults]

:: [Presentations](#)

[MMWR News Synopsis Friday, November 19, 2021](#)

Selected Content

:: [Health Care Access and Use Among Adults with Diabetes During the COVID-19 Pandemic — United States, February–March 2021](#)

:: [Automated Digital Notification of COVID-19 Diagnoses Through Text and Email Messaging — North Carolina, December 2020–January 2021](#)

:: [Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status — Oregon and Washington, July 4–September 25, 2021](#)

:: [Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic — United States, July 2020–July 2021](#)

[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)

Approximately 25 announcements/reports/data summaries.

11/19/21

[CDC Expands Eligibility for COVID-19 Booster Shots to All Adults](#)

11/19/21

[Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 19 Nov 2021 06:00:00 EST](#)

.....

.....

Africa CDC [to 20 Nov 2021]

<http://www.africacdc.org/>

News

Press Releases

[Africa CDC and CDDEP release African Antibiotic Treatment Guidelines for Common Bacterial Infections and Syndromes](#)

Addis Ababa, Ethiopia, 19 November 2021– An interdisciplinary panel of infectious disease clinicians and public health experts led by the Africa Centres for Disease Control and Prevention (Africa CDC) and the Center for Disease Dynamics, Economics & Policy (CDDEP) have released a first edition of the African Antibiotic Treatment Guidelines for Common Bacterial Infections and Syndromes...

The week also marks two years since a unique partnership of six regional organizations was formed to push ahead on fighting AMR in Africa, involving the Tripartite Partners (the Food and Agriculture Organization of the United Nations (FAO), the World Organization for Animal Health (OIE), and the World Health Organization (WHO)), with the UN Environment Programme (UNEP), the Africa Centres

for Disease Control and Prevention (Africa CDC), and the African Union Inter-African Bureau for Animal Resources (AU-IBAR)..

Press Releases

[Stronger governance needed to fight superbugs in Africa Antimicrobial Resistance threatens Africa's development](#)

Addis Ababa, Ethiopia, 17 November 2021– The leaders of six regional organizations in Africa are calling for stronger governance to fight antimicrobial resistance, or AMR, on the eve of World Antimicrobial Awareness Week (18-24 November)...

The week also marks two years since a unique partnership of six regional organizations was formed to push ahead on fighting AMR in Africa, involving the Tripartite Partners (the Food and Agriculture Organization of the United Nations (FAO), the World Organization for Animal Health (OIE), and the World Health Organization (WHO)), with the UN Environment Programme (UNEP), the Africa Centres for Disease Control and Prevention (Africa CDC), and the African Union Inter-African Bureau for Animal Resources (AU-IBAR)..

.....
.....

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 20 Nov 2021]

<http://en.nhc.gov.cn/>

News

[Nov 20: Daily briefing on novel coronavirus cases in China](#)

2021-11-20

On Nov 19, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 23 new cases of confirmed infections (20 imported cases, 6 in Shanghai municipality, 5 in Guangxi Zhuang autonomous region, 4 in Shandong province, 2 in Guangdong province, 2 in Yunnan province and 1 in Fujian province, including 1 confirmed case converting from an asymptomatic case in Guangdong; 3 indigenous cases, 2 in Dalian, Liaoning province and 1 in Jilin, Jilin province), no new cases of suspected infections, and no deaths...

National Medical Products Administration – PRC [to 20 Nov 2021]

<http://english.nmpa.gov.cn/>

News

[COVID-19 vaccine doses administered on Chinese mainland hit 2.4b milestone](#)

2021-11-18

More than 2.4 billion doses of COVID-19 vaccines had been administered on the Chinese mainland as of Nov 16, data from the National Health Commission showed on Nov 17.

[China, US need to initiate global public health, infectious disease response cooperation mechanism: Xi](#)

2021-11-17

President Xi Jinping on Tuesday said that China and the United States need to call for the establishment of a cooperation mechanism for global public health and communicable disease

prevention and control, and promote further international exchanges and cooperation. Xi made the remarks in a virtual meeting with US President Joe Biden...

CCDC Weekly - [Weekly Reports: Current Volume \(3\)](#)

2021-11-19 / No. 47 **WORLD ANTIBIOTIC AWARENESS WEEK ISSUE**

[View PDF of this issue](#)

:: [Foreword: World Antimicrobial Awareness Week 2021 — Spread Awareness, Stop Resistance](#)

:: [Preplanned Studies: Genomic Insight into the Antimicrobial Resistance of Streptococcus Suis — Six Countries, 2011–2019](#)

:: [Preplanned Studies: Prevalence of Escherichia coli and Antibiotic Resistance in Animal-Derived Food Samples — Six Districts, Beijing, China, 2020](#)

:: [Vital Surveillances: Surveillance of Multidrug-Resistant Bacterial Infections in Non-Adult Patients — Zhejiang Province, China, 2014–2019](#)

.....
.....
.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 20 Nov 2021]

<https://alleninstitute.org/news-press/>

News

Press Release

[Allen Institute announces 2021 Next Generation Leaders](#)

November 8, 2021

Six early-career neuroscientists will participate in unique advisory council for the Institute

BARDA – U.S. Department of HHS [to 20 Nov 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

November 18, 2021

[Biden Administration Secures 10 Million Courses of Pfizer's COVID-19 Oral Antiviral Medicine as Additional Tool to Reduce Hospitalizations and Save Lives](#)

Pending EUA, U.S. will receive doses starting in 2021 and throughout 2022 as part of contract agreement with Pfizer

BMGF - Gates Foundation [to 20 Nov 2021]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 20 Nov 2021]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.*

CARB-X [to 20 Nov 2021]

<https://carb-x.org/>

News

11.19.2021

Partnering to Protect: Public & Private Sectors Unite Against Antimicrobial Resistance

A webinar convening international experts allowed us to explore the barriers to building a robust pipeline of next generation AMR innovation. The key message: AMR is a global challenge, and we must work together as an international community to spur innovation, support whole-of-ecosystem changes, and learn from one another's different approaches.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 20 Nov 2021]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **Informed Consent: A Monthly Review – November 2021** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 20 Nov 2021]

<http://cepi.net/>

Latest News

CEPI and Clover expand partnership for COVID-19 vaccine to include evaluation as a booster

18 Nov 2021

– CEPI commits up to an additional US\$36.9 million for a total investment of up to \$397.4 million to support the development of Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum)

-CEPI funding supports development of SCB-2019 (CpG 1018/Alum) for primary vaccination across all age groups (pediatric, adolescent, adults, and elderly) and development as a potential booster

DARPA – Defense Advanced Research Projects Agency [to 20 Nov 2021]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 20 Nov 2021]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 20 Nov 2021]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

19 November 2021

[Legal basis for Global Health EDCTP3 Joint Undertaking adopted](#)

The European Commission today announced the adoption of 10 European Partnerships set up between the European Union, Member States and/or the industry, including the Global Health EDCTP3 Partnership. The EU will provide nearly €10 billion of funding that the partnerships will match with at least an equivalent amount of investment.

16 November 2021

[Completion of Phase III trial paediatric schistosomiasis drug arpraziquantel](#)

Emory Vaccine Center [to 20 Nov 2021]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 20 Nov 2021]

<http://www.euvaccine.eu/>

Latest News News, Events

No new digest content identified.

Fondation Merieux [to 20 Nov 2021]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 20 Nov 2021]

<https://www.gavi.org/>

News Releases

19 November 2021

[Luxembourg stands up for equitable access by donating doses to COVAX – first doses reach Rwanda](#)

...Luxembourg has donated 409,600 doses of COVAX-19 vaccines to COVAX, with the first 12,000 doses reaching Rwanda. This donation comes on top of a previous EUR 2 million pledge to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC) to support procurement of vaccines for lower-income economies around the world, which Luxembourg has now increased by 2 million to a total of EUR 4 million.

16 November 2021

[Gavi and humanitarian agencies partner to deliver COVID-19 vaccines to the most vulnerable people in the world](#)

16 November 2021

[First Greek COVAX doses arrive in Kenya and Syria](#)

:: The first shipments of a 3 million dose pledge to COVAX thus far by Greece have arrived in Kenya (376,800 doses) and Syria (144,000). This builds on previous funding commitments of EUR 1.5 million to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC).

GHIT Fund [to 20 Nov 2021]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
November 16, 2021

[The Pediatric Praziquantel Consortium Announces Positive Phase III Results for Arpraziquantel To Treat Schistosomiasis](#)

Global Fund [to 20 Nov 2021]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

[Inequitable access to COVID-19 tools is hindering the pandemic response](#)

16 November 2021

A snapshot across 503 facilities in Africa, Asia, and Eastern Europe and Central Asia

A new snapshot reveals the persistent and glaring inequity in access to lifesaving COVID-19 tools, such as diagnostic tests, treatments (including medical oxygen), and personal protective equipment (PPE), that is hindering the pandemic response in low- and middle-income countries.

This inequity is creating a two-track pandemic; while rich countries with high vaccination rates are largely returning to normal life, low- and middle-income countries continue to suffer high death rates and lockdowns, due to shortages of lifesaving tests, treatments and vaccines. Not only is this morally wrong, but this situation also creates the perfect conditions for new variants to emerge, which threaten any global progress and will continue to prolong the pandemic indefinitely.

The snapshot provides an indicative update of countries' access to COVID-19 tools through spot checks conducted in 503 facilities in 33 countries across the regions of Africa, Asia, and Eastern Europe and Central Asia (EECA) between May and September 2021.

The indicative data is concerning. Less than half of the 503 facilities across Africa, Asia, and Eastern Europe could conduct COVID-19 tests, meaning that countries cannot track or contain the spread of the virus, implement test and treat strategies, or detect the emergence of new variants. Medical oxygen is also not accessible everywhere, and many COVID-19 patients have died, and continue to die,

for lack of oxygen. The snapshot also highlights the higher risk run by health workers of contracting COVID-19, which is exacerbated by a lack of access to lifesaving PPE...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 20 Nov 2021]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 20 Nov 2021]

<http://www.hillemanlabs.org/>

No new digest content identified....No "news" page or tab.

HHMI - Howard Hughes Medical Institute [to 20 Nov 2021]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Vaccines Project [to 20 Nov 2021]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 20 Nov 2021]

<https://www.iavi.org/newsroom>

Latest News

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 20 Nov 2021]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

[ICRC and IFRC on migration crisis at the borders between Belarus, Poland, Lithuania and other countries](#)

Budapest/Geneva - November 18, 2021 — The International Federation of Red Cross and Red Crescent Societies (IFRC) and the International Committee of the Red Cross (ICRC) are alarmed by the humanitarian tragedy unfolding at the borders between Belarus

18-11-2021 | Statement

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

[IFFIm increases its most recent bond by US\\$ 250 million to total US\\$ 1 billion](#)

18 Nov 2021

:: The US\$ 250 million increase will bring the total size of the April 2026 bond to US\$ 1 billion.

:: The proceeds will provide US\$ 250 million in additional funding for Gavi's core immunisation programmes and the Gavi COVAX Advance Market Commitment (AMC).

IFFIm today increased by US\$ 250 million the 1% 5-year vaccine bond it issued in April 2021. The additional proceeds will provide Gavi, the Vaccine Alliance, immediately available funding to support routine immunisation in lower-income countries.

IFRC [to 20 Nov 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

19/11/2021

["We need to do better" – IFRC report reveals gaps in child protection during climate related disasters](#)

18/11/2021

[Joint statement by IFRC and ICRC on migration crisis at the borders between Belarus, Poland, Lithuania and other countries](#)

15/11/2021

[Action needed now to prevent further loss of life on...](#)

15/11/2021

[IFRC and TNC urge governments to invest in climate change...](#)

13/11/2021

[COP26: More than vague promises are needed to save m...](#)

Institut Pasteur [to 20 Nov 2021]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 20 Nov 2021]

<http://www.iom.int/press-room/press-releases>

News - Selected

No new digest content identified.

ISC / International Science Council [to 20 Nov 2021]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News

[UNESCO Science Commission adopts Open Science Recommendation](#)

The UNESCO recommendation on Open Science has been unanimously adopted in its entirety by Member States during the Science Commission plenary.

15.11.2021

IVAC [to 20 Nov 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 20 Nov 2021]

<http://www.ivi.int/>

IVI News & Announcements

[IVI leaders address health security at 'first World Emerging Security Forum' in Seoul](#)

Dr. Jerome Kim, Director General and Dr. Song Manki, Deputy Director General of Science of the International Vaccine Institute (IVI) joined distinguished global leaders and experts as moderator and speaker at the first World Emerging Security Forum, which took place in Seoul on November 16 and 17, 2021.

[World Antimicrobial Awareness Week 2021: Accelerate vaccines. Stop AMR.](#)

[Undated]

Johns Hopkins Center for Health Security [to 20 Nov 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

No new digest content identified.

MSF/Médecins Sans Frontières [to 20 Nov 2021]

<http://www.msf.org/>

Latest [Selected Announcements]

No new digest content identified.

National Academy of Medicine - USA [to 20 Nov 2021]

<https://nam.edu/programs/>

Selected News/Programs/Events

Four New Reports from the National Academy of Medicine Focus on How to Prepare for Seasonal and Pandemic Influenza Through Lessons Learned from COVID-19

November 17, 2021

The NAM released four reports on applying lessons learned from COVID-19 to prepare for seasonal influenza, as well as the next influenza pandemic. The reports provide recommendations on leveraging COVID-19 vaccine technology for influenza vaccine research and development, bolstering the influenza vaccine supply chain, improving global coordination, and effectively using non-vaccine public health measures, such [...]

National Academy of Sciences - USA [to 20 Nov 2021]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 20 Nov 2021]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 20 Nov 2021]

<http://www.nih.gov/news-events/news-releases>

News Releases

Lung autopsies of COVID-19 patients reveal treatment clues

November 17, 2021 — SARS-CoV-2 prevents lung tissue repair, regeneration.

Long-term study of children with COVID-19 begins

November 15, 2021 — NIH-supported research will track effects of COVID-19 infection on children over three years.

OECD [to 20 Nov 2021]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

Newsroom

16-November-2021

People are increasingly worried about inequalities but divided on how to address them, says OECD

For a recovery from the Covid-19 crisis that is strong, sustainable but also fair, it will be key to tackle inequalities and promote equal opportunities. Yet while there is growing consensus that inequality is a problem, people are increasingly divided about its extent and what to do about it, according to a new OECD report.

PATH [to 20 Nov 2021]

<https://www.path.org/media-center/>

Press Releases

[PATH and the Helmsley Charitable Trust partner to improve access to safe administration of insulin and self-care for people living with diabetes](#)

A century after the discovery of insulin, millions of people living with diabetes cannot obtain or afford the necessary supplies to self-manage their diabetes on a day-to-day basis. PATH partners with the Helmsley Charitable Trust to improve access to diabetes self-care in Mali, Mozambique, and Tanzania.

Published: November 2021

Type: Press Release

[A supply gap of more than 1 billion autodisable syringes could impact COVID-19 immunization efforts in 100 countries](#)

Global convening of syringe manufacturers and multilateral organizations held to help bolster supply.

Published: November 2021

Type: Press Release

[See COVID above for detail]

[PATH congratulates India on nationwide pneumococcal vaccine introduction](#)

Routine childhood immunization with pneumococcal vaccines is a critical step in India's fight against pneumonia and other pneumococcal diseases.

Published: November 2021

Type: Statement

Sabin Vaccine Institute [to 20 Nov 2021]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 20 Nov 2021]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

17 November 2021

[Supporting people living with HIV with income generation in the Central African Republic](#)

16 November 2021

[UNAIDS Respect campaign against abusive conduct](#)

15 November 2021

[Race affecting HIV service provision in the United States of America](#)

UNHCR Office of the United Nations High Commissioner for Refugees [to 20 Nov 2021]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

[UNHCR report charts progress against Global Compact on Refugees](#)

16 November 2021

A new [report](#) released today by UNHCR, the UN Refugee Agency, shows how far the international community has come since it called for the development of a new international framework to share responsibility for refugee situations – the Global Compact on Refugees (GCR).

The first GCR Indicator Report covers the years 2016 to 2021 and shows progress has been made in increasing support for low-income countries hosting refugees and in expanding refugees' access to work and education. The report warns however, that much more remains to be done.

"The picture that has emerged is mixed. We see that countries with the fewest resources continue to bear the most responsibility for both new and protracted refugee situations. At the same time, we are seeing some good indications of progress by states, the private sector, civil society, and development banks in helping to try and bridge the gap," said Gillian Triggs, UNHCR's Assistant High Commissioner for Protection.

The report shows that while more financing for refugee humanitarian and development responses is needed, there has been an upward trend in bilateral development assistance channelled to low-income refugee host countries since 2016.

Development banks are also playing a larger role in responding to crises providing at least US\$2.33 billion. The number of refugee situations supported by the World Bank for example increased from two to 19...

UNICEF [to 20 Nov 2021]

<https://www.unicef.org/media/press-releases>

*Press Releases, News Notes, Statements [Selected]
Remarks*

11/19/2021

[Remarks by UNICEF Executive Director Henrietta Fore at the launch of the Spotlight Initiative Impact Report 2020-2021](#)

As prepared for delivery

"The initiative is the world's largest targeted effort to end all forms of violence against women and girls. It is working to change the harmful social and gender norms that underpin violence. And it is improving access to – and the quality of – essential services for survivors of violence."

Press release

11/14/2021

[More than 45,000 children released from detention during COVID-19 pandemic; evidence that child-friendly justice solutions are possible – UNICEF](#)

Ahead of the World Congress on Justice with Children, a new UNICEF analysis estimates more than 261,000 children are held in detention globally; calls for juvenile justice reform to end detention of all children

Unitaid [to 20 Nov 2021]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 20 Nov 2021]

<https://vaccineequitycooperative.org/news/>

News

Nov 15, 2021

[Blog: Addressing Systemic Inequities and Racism in Community-Based Organization Funding](#)

It has never been more critical to document and amplify lessons learned from our nation's pandemic response in order to shift how we perceive, value and fund CBOs and CBWs.

Vaccination Acceptance & Demand Initiative [Sabin] [to 20 Nov 2021]

<https://www.vaccineacceptance.org/>

Announcements

Blog

[Sabin's New Director of Research Embraces Challenge of Global Vaccine Equity](#)

November 2021

Kate Hopkins reflects on how her previous work in sub-Saharan Africa prepared her to join Sabin in addressing vaccine acceptance and demand globally.

Blog

[Sabin Welcomes 10 Partners to the 2021 Social and Behavioral Grants Program](#)

November 2021

Interdisciplinary teams will explore vaccine acceptance, uptake strategies and locally suitable solutions.

Vaccine Confidence Project [to 20 Nov 2021]

<http://www.vaccineconfidence.org/>

News, Research and Reports

[Coronavirus global impact](#)

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Vaccine Education Center – Children's Hospital of Philadelphia [to 20 Nov 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 20 Nov 2021]

<https://wellcome.ac.uk/news>

News and reports

Opinion

Author - Beth Thompson

[Science's role in protecting health from climate change isn't done](#)

16 November 2021

The Wistar Institute [to 20 Nov 2021]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 20 Nov 2021]

<https://www.wfpha.org/>

Latest News

[Evidence-based Leadership Is more Important than ever before!](#)

Nov 17, 2021

Evidence-based Leadership Is more Important than ever before! A Reflection by Public Health Leadership Coalition's Member - Prof. Walter Ricciardi The COVID-19 pandemic acted like a global tsunami, exacerbating the existing challenges and focusing...

World Bank [to 20 Nov 2021]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

[New World Bank report: Remote Learning during the pandemic: Lessons from today, principles for tomorrow](#)

WASHINGTON, D.C., Nov. 18, 2021— Education systems around the world reacted to COVID-19 by closing schools and rolling out remote learning options for their students as an emergency response. New...

Date: November 18, 2021 Type: Press Release

[Addressing Food Insecurity and Boosting the Resilience of Food Systems in West Africa](#)

World Bank approves a \$570 million Multi-Phase Programmatic Approach Program to improve food system resilience, promote intraregional value chains, and build regional capacity to manage agricultural risks...

Date: November 18, 2021 Type: Press Release

[Remittance Flows Register Robust 7.3 Percent Growth in 2021](#)

WASHINGTON, Nov 17, 2021 — Remittances to low- and middle-income countries are projected to have grown a strong 7.3 percent to reach \$589 billion in 2021. This return to growth is more robust than earlier...

Date: November 17, 2021 Type: Press Release

[Social Protection for the Informal Economy: Operational Lessons for Developing Countries in Africa and Beyond](#)

November 17, 2021 — The size of the informal economy as a share of GDP in Africa is the largest in the world and with most jobs expected to be created in the informal economy, they will continue to be...

Date: November 17, 2021 Type: Publication

[World Bank to Provide Strategic Support for Social and Economic Integration of Venezuelan Migrants in Colombia](#)

WASHINGTON, November 16, 2021 – The World Bank Board of Executive Directors approved a US\$500 million loan today aimed at supporting the Colombian government’s strategy for the social and economic integration...

Date: November 16, 2021 Type: Press Release

World Organisation for Animal Health (OIE) [to 20 Nov 2021]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

[The World Organisation for Animal Health \(OIE\) calls for increased surveillance of avian influenza as outbreaks in poultry and wild birds intensify](#)

Press Release 19 November 2021

[See Milestones above for detail]

WTO - World Trade Organisation [to 20 Nov 2021]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

[Members to continue discussion on a common COVID-19 IP response up until MC12](#)

18 November 2021

At a formal meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 18 November, WTO members agreed to keep actively engaging up until the WTO’s 12th Ministerial Conference (MC12) in order to find a common intellectual property (IP) response to COVID-19. The chair of the Council, Ambassador Dagfinn Sørli of Norway, said he will make sure no stone is left unturned to explore all available options towards a consensus-based outcome at the Ministerial Conference taking place from 30 November to 3 December.

[See COVID above for detail]

[Vulnerabilities, resilience in global trading system examined in World Trade Report 2021](#)

16 November 2021

The 2021 edition of the WTO’s World Trade Report examines why the interconnected global trading system is both vulnerable and resilient to crises such as the COVID-19 pandemic, how it can help countries to be more economically resilient to shocks, and what can be done to make the system better prepared and more resilient in the future. The flagship publication, launched on 16 November, notes the need to address these issues in light of the prospect of increasingly frequent and more intense natural and man-made disasters.

.....

ARM [Alliance for Regenerative Medicine] [to 20 Nov 2021]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 20 Nov 2021]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

Patients Empowered with New “Clinical Trials: The Power of Participation” Website

November 16, 2021

The Biotechnology Innovation Organization (BIO) today announced the launch of *Clinical Trials: The Power of Participation (CTPoP)*, a website that addresses how clinical trials work, how to enroll in a clinical trial, and what to expect as a clinical...

DCVMN – Developing Country Vaccine Manufacturers Network [to 20 Nov 2021]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 20 Nov 2021]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 20 Nov 2021]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

20 leading research, medical and pharmaceutical organizations call on G7 to step up action to strengthen the R&D antibiotic pipeline

17 November 2021

Ahead of the “World Antimicrobial Awareness Week” (November 18-24) 20 national and international organizations from academia, healthcare and the pharmaceutical industry appealed today to G7 governments to step up efforts to tackle the problem of growing antibiotic resistance. In a [joint statement](#), they stress that only an approach involving both the public and private sectors can succeed in revitalizing the antibiotic clinical pipeline by rewarding innovation.

They emphasize that it is important to ensure that:

- new economic incentives are implemented that sufficiently reward successful development of new antibiotics,
- new antibiotics against hard-to-at pathogens reach patients quickly,
- the potential of vaccines to reduce the risk of bacterial infections is fully leveraged, and
- antibiotics of today and of the future are used even more rationally.

In 2022, during its G7 presidency, Germany must play a leading role in engaging effectively within the global framework of anti-microbial resistance-related measures that address R&D, market access, as well as effective antibiotic stewardship. Similarly, Germany should take the opportunity to ensure that solutions continue to be worked toward under the subsequent Japanese G7 presidency in 2023...

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 20 Nov 2021]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 20 Nov 2021]

<http://www.phrma.org/>

Latest News [Selected]

Five Key Strategies for Enhancing Diversity in Clinical Trials

Report based on more than a year of research and feedback from more than 500 stakeholders across 150+ organizations

Nov 16, 2021

A new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Deloitte Center for Health Solutions (CHS) outlines five critical strategies for enhancing diversity in clinical trials during the research and development of new medicines. The report, titled "Enhancing Clinical Trial Diversity: Stakeholder Perspectives on Advancing Research Through Representative Clinical Trials," is based on a year-long stakeholder engagement effort that included research and feedback from more than 500 stakeholders across 150+ organizations, including community stakeholders, experts in clinical trials and in racial justice, patient advocates, health care practitioners, pharmaceutical companies, academia, and more...

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 11: E833-904

<https://journalofethics.ama-assn.org/issue/health-care-and-homelessness>

Health Care and Homelessness

Homelessness dramatically undermines personal and community health status. Throughout their lifespans, children, elders, and all who are chronically unsheltered confront cumulative health detriments of exposure, violence, and poor nutrition. With limited access to hygiene opportunities and health services, people experiencing homelessness endure poor continuity of care and some of the poorest health outcomes tolerated in the US health care system.

[Reviewed earlier]

American Journal of Infection Control

November 2021 Volume 49 Issue 11 p1343-1456

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

November 2021 Volume 61 Issue 5 p619-770

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

November 2021 111(11)

<http://ajph.aphapublications.org/toc/ajph/current>

EDITORIALS

[An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher](#)

Government, Immunization/Vaccines, Health Law

Reshma Ramachandran, Ravi Gupta and Jing Luo

111(11), pp. 1923–1926

OPEN-THEMED RESEARCH

[Vaccine Coverage Across the Life Course in Michigan During the COVID-19 Pandemic: January–September 2020](#)

Immunization/Vaccines, Epidemiology

Angela K. Shen, Cristi A. Bramer, Lynsey M. Kimmins, Robert Swanson, Patricia Vranesich and Walter Orenstein

111(11), pp. 2027–2035

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 2 (Aug 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/2/tpmd.105.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

November 2021 Volume 174, Issue 11

<http://annals.org/aim/issue>

Original Research

[The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy - A Randomized Controlled Trial](#)

Jeffrey R. Curtis, MD, MS, MPH, Stacey S. Cofield, PhD, S. Louis Bridges Jr., MD, PhD, John Bassler, MS, [... et al.](#)

[What Will It Take to End HIV in the United States? A Comprehensive, Local-Level Modeling Study](#)

Anthony Todd Fojo, MD, MHS, Melissa Schnure, ScM, Parastu Kasaie, PhD, [... et al.](#)
Pages:1542–1553

[Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 A Prospective Cohort Study](#)

FREE

Parakkal Deepak, MBBS, MS, Wooseob Kim, PhD, Michael A. Paley, MD, PhD, Monica Yang, MD, [... et al.](#)

Pages:1572–1585

[Population Immunity Against COVID-19 in the United States](#)

FREE

Seyed M. Moghadas, PhD, Pratha Sah, PhD, Affan Shoukat, PhD, Lauren Ancel Meyers, PhD, [... et al.](#)
Pages:1586–1591

Artificial Intelligence – An International Journal

Volume 300 November 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/300/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 20 Nov 2021)

[No new digest content identified]

BMJ Global Health

November 2021 - Volume 6 - 11

<https://gh.bmj.com/content/6/11>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 20 Nov 2021)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 20 Nov 2021)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 20 Nov 2021)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 20 Nov 2021)

[Effect of evidence updates on key determinants of measles vaccination impact: a DynaMICE modelling study in ten high-burden countries](#)

Model-based estimates of measles burden and the impact of measles-containing vaccine (MCV) are crucial for global health priority setting. Recently, evidence from systematic reviews and database analyses have ...

Authors: Han Fu, Kaja Abbas, Petra Klepac, Kevin van Zandvoort, Hira Tanvir, Allison Portnoy and Mark Jit

Citation: BMC Medicine 2021 19:281

Content type: Research article

Published on: 17 November 2021

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 20 Nov 2021)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 20 Nov 2021)

[Community perceptions of vaccination among influential stakeholders: qualitative research in rural India](#)

In India and other low- and middle-income countries, multiple family and community members are influential in caregivers' perceptions of vaccination. Existing literature indicates the primary caregiver, typica...

Authors: Baldeep K. Dhaliwal, Riti Chandrashekhar, Ananya Rattani, Rajeev Seth, Svea Closser, Anika Jain, David E. Bloom and Anita Shet

Citation: BMC Public Health 2021 21:2122

Content type: Research article

Published on: 18 November 2021

Knowledge of mothers regarding children's vaccinations in Greece: an online cross-sectional study

One of the main reasons that influence parental choice to postpone or avoid children's vaccination is insufficient knowledge. Mothers' knowledge can be considered as an important factor when determining childc...

Authors: Konstantinos Giannakou, Maria Kyprianidou, Andria Hadjickou, Georgia Fakonti, Galatia Photiou, Eleana Tzira and Alexandros Heraclides

Citation: BMC Public Health 2021 21:2119

Content type: Research

Published on: 18 November 2021

COVID-19 vaccination acceptance among Syrian population: a nationwide cross-sectional study

Severe Acute Respiratory Syndrome Coronavirus 2 continues to spread globally and in the absence of an effective treatment, the vaccine remains the best hope for controlling this disease. In this study, we seek...

Authors: Mosa Shibani, Mhd Amin Alzabibi, Abd El-Fattah Mouhandes, Tamim Alsuliman, Angie Mouki, Hlma Ismail, Shahd Alhayk, Ahmad Abdulateef Rmman, Marah Mansour, Marah Marrayi, Nawras Alhalabi, Mhd Baraa Habib, Mhd Kutaiba Albuni, Ahmad Al-Moujahed and Bisher Sawaf

Citation: BMC Public Health 2021 21:2117

Content type: Research

Published on: 18 November 2021

COVID19 vaccine intentions in South Africa: health communication strategy to address vaccine hesitancy

Vaccine hesitancy is emerging as a significant challenge in many parts of the world in the fight against the COVID19 pandemic. The continued infection amongst the unvaccinated can lead to a heightened risk of ...

Authors: Umakrishnan Kollamparambil, Adeola Oyenubi and Chijioke Nwosu

Citation: BMC Public Health 2021 21:2113

Content type: Research

Published on: 17 November 2021

Racial differences in institutional trust and COVID-19 vaccine hesitancy and refusal

Previous research has indicated that demographic differences affect COVID-19 vaccination rates. Trust, in both the vaccine itself and institutional trust, is one possible factor. The present study examines rac...

Authors: Anisah B. Bagasra, Sara Doan and Christopher T. Allen

Citation: BMC Public Health 2021 21:2104

Content type: Research

Published on: 16 November 2021

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 20 Nov 2021)

[No new digest content identified]

BMJ Evidence-Based Medicine

October 2021 - Volume 26 - 5

<https://ebm.bmj.com/content/26/5>

[Reviewed earlier]

BMJ Open

November 2021 - Volume 11 - 11

<https://bmjopen.bmj.com/content/11/11>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99(11); 2021 Nov 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/392423/>

[Reviewed earlier]

Cell

Nov 11, 2021 Volume 184 Issue 23 p5691-5838

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 47, Issue 6 Pages: 733-885 November 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 110, Issue 5 Pages: 1137-1402 November 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

October 2021 Volume 43 Issue 10 p1627-1808

<http://www.clinicaltherapeutics.com/current>

CONVERSATIONS WITH THE EDITORS

[**Conversations With the Editors: The Emergence of Variants Amid Population-Wide SARS-CoV-2 Vaccination Efforts: How Much Should We Worry?**](#)

Egon Ozer, Larry K. Kociolek, Ravi Jhaveri

Published online: July 25, 2021

p1630-1635

Commentary

Behavioral Economics as a Model to Improve Adolescent and Adult Vaccination

Rachel Caskey

Published online: August 03, 2021

p1649-1653

Despite that fact that the first scientifically based smallpox vaccine was developed in the late 1700s, in 2021 we struggle to fully vaccinate adolescents and adults in the United States. Decades of scientific data support the efficacy and tolerability of vaccines in general, yet vaccine hesitancy remains common. Fear sits much deeper than logic within the human psyche, especially when it comes to vaccine decision making. The complexities of human psychology and decision making are the footings of vaccine hesitancy and yet may also provide an opportunity to shift vaccination behavior.

Clinical Trials

Volume 18 Issue 6, December 2021

<https://journals.sagepub.com/toc/ctja/18/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 20 Nov 2021]

[No new digest content identified]

Contemporary Clinical Trials

Volume 110 November 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/110/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 4, Issue 5 / October 2021

<https://www.liebertpub.com/toc/crispr/4/5>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 3, September 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

October 2021 - Volume 34 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

TROPICAL AND TRAVEL-ASSOCIATED DISEASES

Edited by Christina M. Coyle

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 3 Pages: 97-148 September 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 31, Issue 7, 2021

<http://www.tandfonline.com/toc/cdip20/current>

The Private Sector in the Development Landscape.

Guest Editors: Jason Hart, Jo-Anna Russon & Jessica Sklair

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 4 - August 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 45, Issue 4 Pages: 739-995 October 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 22 Issue 11 4 November 2021

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 27, Number 11—November 2021

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 36 September 2021

<https://www.sciencedirect.com/journal/epidemics/vol/36/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 6 Pages: 1-48 November–December 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

Articles

[Physician Perspectives on Including Pregnant Women in Covid-19 Clinical Trials: Time for a Paradigm Change](#)

[Marie-Julie Trahan](#), [Annabelle Cumyn](#), [Matthew P. Cheng](#), [Emily G. McDonald](#), [Stephen E. Lapinsky](#), [Nick Daneman](#), [Haim A. Abenheim](#), [Isabelle Malhamé](#)

Pages: 19-27

First Published: 26 October 2021

Ethics & International Affairs

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.

[Reviewed earlier]

Ethics, Medicine and Public Health

September 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/18/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 31, Issue 5, October 2021

<https://academic.oup.com/eurpub/issue/31/5>

[Reviewed earlier]

Expert Review of Vaccines

Vol 20 (10) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 20 Nov 2021]

[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 3 September 30, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 20 Nov 2021]

[No new digest content identified]

Global Public Health

Volume 16, Issue 12 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 20 Nov 2021]

[No new digest content identified]

Health and Human Rights

Volume 23, Issue 1, June 2021

<https://www.hhrjournal.org/volume-23-issue-1-june-2021/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 4 - October 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 9, November 2021

<https://academic.oup.com/heapol/issue/36/9>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 20 Nov 2021]

[No new digest content identified]

Human Gene Therapy

Volume 32, Issue 19-20 / October 2021

<https://www.liebertpub.com/toc/hum/32/19-20>

[Reviewed earlier]

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

Localisation and local humanitarian action

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain

between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 10, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Immunity

Nov 09, 2021 Volume 54 Issue 11 p2437-2670

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 20 Nov 2021]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 20 Nov 2021]

Scoping Review

[Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis](#)

To date, coronavirus disease 2019 (COVID-19) becomes increasingly fierce due to the emergence of variants. Rapid herd immunity through vaccination is needed to block the mutation and prevent the emergence of variants that can completely escape the immune surveillance. We aimed to systematically evaluate the effectiveness and safety of COVID-19 vaccines in the real world and to establish a reliable evidence-based basis for the actual protective effect of the COVID-19 vaccines, especially in the ensuing waves of infections dominated by variants.

Authors: Qiao Liu, Chenyuan Qin, Min Liu and Jue Liu

14 November 2021

International Health

Volume 13, Issue 5, September 2021

<https://academic.oup.com/inthealth/issue/13/5>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 8, No 10 (2021) October 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/81>

[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 5, October 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

October 2021 Volume 111 p1-362

<https://www.ijidonline.com/current>

[Reviewed earlier]

JAMA

November 16, 2021, Vol 326, No. 19, Pages 1891-1983

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

[Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar](#)

Laith J. Abu-Raddad, PhD; Hiam Chemaitelly, MSc; Houssein H. Ayoub, PhD; et al.

free access has active quiz

JAMA. 2021;326(19):1930-1939. doi:10.1001/jama.2021.19623

This cohort study assesses protection from SARS-CoV-2 breakthrough infection after mRNA vaccination among persons with vs without prior SARS-CoV-2 infection.

[Changes in COVID-19 Vaccine Intent From April/May to June/July 2021](#)

Peter G. Szilagyi, MD, MPH; Kyla Thomas, PhD; Megha D. Shah, MD, MPH, MS; et al.

free access

JAMA. 2021;326(19):1971-1974. doi:10.1001/jama.2021.18761

This study uses data from a nationally representative longitudinal study of adults in the US to examine individual-level change in vaccine intent and uptake between April and July 2021.

JAMA Network

COVID-19 Update November 20, 2021

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

November 2021, Vol 175, No. 11, Pages 1093-1192
<https://jamanetwork.com/journals/jamapediatrics/currentissue>
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>
[Reviewed earlier]

JBI Evidence Synthesis

November 2021 - Volume 19 - Issue 11
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>
[New issue; No digest content identified]

Journal of Adolescent Health

November 2021 Volume 69 Issue 5
<https://www.jahonline.org/current>
[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 72 (2021)
<https://www.jair.org/index.php/jair>
[Reviewed earlier]

Journal of Community Health

Volume 46, issue 5, October 2021
<https://link.springer.com/journal/10900/volumes-and-issues/46-5>
[Reviewed earlier]

Journal of Development Economics

Volume 153 November 2021
<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/153/suppl/C>
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 5, December 2021
<http://journals.sagepub.com/toc/jre/current>
[Reviewed earlier]

Journal of Epidemiology & Community Health

November 2021 - Volume 75 - 11
<https://jech.bmj.com/content/75/11>

Social inequalities

[Indigenous Peoples, concentrated disadvantage, and income inequality in New Mexico: a ZIP code-level investigation of spatially varying associations between socioeconomic disadvantages and confirmed COVID-19 cases](#) (23 March, 2021) Free

Kimberly R Huysen, Tse-Chuan Yang, Aggie J Yellow Horse

[Social deprivation as a risk factor for COVID-19 mortality among women and men in the UK Biobank: nature of risk and context suggests that social interventions are essential to mitigate the effects of future pandemics](#) (27 April, 2021)

Mark Woodward, Sanne A E Peters, Katie Harris

Journal of Evidence-Based Medicine

Volume 14, Issue 3 Pages: 171-256 September 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 17, Issue 1, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 3, August 2021

<https://muse.jhu.edu/issue/45771>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 23, issue 5, October 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>

[Reviewed earlier]

Journal of Medical Ethics

November 2021 - Volume 47 - 11

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 4 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

Cancer Screening

[Reviewed earlier]

Journal of Pediatrics

November 2021 Volume 238 p1-348

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 20 Nov 2021]

[No new digest content identified]

Journal of Public Health Management & Practice

November/December 2021 - Volume 27 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 3, September 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-3>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

November 2021 Volume 18 Issue 184

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 7, October 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 95 • Number 21 • October 2021

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Nov 20, 2021 Volume 398 Number 10314 p1851-1938

<https://www.thelancet.com/journals/lancet/issue/current>

Articles

[Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000–17: a financial modelling study](#)

Gloria Ikilezi, Angela E Micah, Steven D Bachmeier, Ian E Cogswell, Emilie R Maddison, Hayley N Stutzman, Golsum Tsakalos, Logan Brenzel, Joseph L Dieleman

Open Access

Childhood immunisation is one of the most cost-effective health interventions. However, despite its known value, global access to vaccines remains far from complete. Although supply-side constraints lead to inadequate vaccine coverage in many health systems, there is no comprehensive analysis of the funding for immunisation. We aimed to fill this gap by generating estimates of funding for immunisation disaggregated by the source of funding and the type of activities in order to highlight the funding landscape for immunisation and inform policy making.

The Lancet Child & Adolescent Health

Nov 2021 Volume 5 Number 11 p767-836

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Nov 2021 Volume 3 Number 11 e684-e750

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Nov 2021 Volume 9 Number 11 e1474-e1622

<https://www.thelancet.com/journals/langlo/issue/current>
[Reviewed earlier]

Lancet Infectious Diseases

Nov 2021 Volume 21 Number 11 p1471-1612, e341-e362
<https://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Nov 2021 Volume 6 Number 11 e780-e865
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Nov 2021 Volume 9 Number 11 p1203-1342, e104-e109
<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 25, issue 11, November 2021
<https://link.springer.com/journal/10995/volumes-and-issues/25-11>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 41 Issue 8, November 2021
<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 99, Issue 3 Pages: 601-852 September 2021
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Nature

Volume 599 Issue 7885, 18 November 2021
<https://www.nature.com/nature/volumes/599/issues/7885>
Article | 21 September 2021

[**Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy**](#)

Optimization of monoclonal antibodies against SARS-CoV-2 for enhanced Fc-effector function increase their effectiveness for prevention and treatment of COVID-19 in multiple animal models of SARS-CoV-2 infection.

Rachel Yamin, Andrew T. Jones, Stylianos Bournazos

Article | 27 October 2021

[**A synthetic antibiotic class overcoming bacterial multidrug resistance**](#)

Structure-guided design and component-based synthesis are used to produce iboxamycin, a novel ribosome-binding antibiotic with potent activity against Gram-positive and Gram-negative bacteria.

Matthew J. Mitcheltree, Amarnath Pisipati, Andrew G. Myers

Nature Biotechnology

Volume 39 Issue 11, November 2021

<https://www.nature.com/nbt/volumes/39/issues/11>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 20 Nov 2021)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 11, November 2021

<https://www.nature.com/ng/volumes/53/issues/11>

[Reviewed earlier]

Nature Human Behaviour

Volume 5 Issue 11, November 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/11>

Comment | 01 November 2021

[**How conspiracists exploited COVID-19 science**](#)

During the COVID-19 pandemic, conspiracy theorists have exploited the provisional nature of scientific consensus and the realities of how science is conducted to paint scientists and public health leaders as malign actors.

Kathleen Hall Jamieson

Article / 17 May 2021

[**The natural selection of good science**](#)

Scientists fear that systemic incentives lead to poor science. Stewart and Plotkin use modelling to show how a scientific process emphasizing the use of theory to select hypotheses can allow good science to thrive in the face of pressure to publish.

Alexander J. Stewart, Joshua B. Plotkin

Article | 13 October 2021

[Science skepticism reduced compliance with COVID-19 shelter-in-place policies in the United States](#)

Brzezinski et al. establish a link between science skepticism and compliance with COVID-19 shelter-in-place policies in the United States during March and April 2020. This relationship persists after controlling for political partisanship, socio-economic factors, income, education and COVID-19 prevalence.

Adam Brzezinski, Valentin Kecht, Austin L. Wright

Article | 17 May 2021

[Trust in science, social consensus and vaccine confidence](#)

Trust in science is important for vaccine confidence, and this is true for countries as well as individuals. Sturgis et al. find that confidence in vaccination is higher in countries where people agree that scientists are trustworthy.

Patrick Sturgis, Ian Brunton-Smith, Jonathan Jackson

Nature Medicine

Volume 27 Issue 11, November 2021

<https://www.nature.com/nm/volumes/27/issues/11>

Diversity, Equity and Inclusion in medical research

In this issue, Nature Medicine is launching a Series on Diversity, Equity and Inclusion in medical research. The first installment brings a perspective on the role of funders in addressing the continued lack of diversity in science and medicine in the United States, and an overview of how governmental, societal and philanthropic stakeholders are approaching lack of diversity and inequalities in their research programs.

Editorial | 11 November 2021

[Diversity, equity and inclusion: we are in it for the long run](#)

We are launching a series on Diversity, Equity and Inclusion in medical research and are redoubling our commitment to representation in our pages.

Article | 30 September 2021

[Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors](#)

After two doses of the BNT162b2 vaccine, virus-specific antibodies and T cells were reduced in patients with solid tumors as compared to individuals without cancer, but neutralizing antibodies increased in most patients who received a third vaccine dose.

Rachna T. Shroff, Pavani Chalasani, Deepta Bhattacharya

Article | 09 September 2021 | Open Access

[Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial](#)

A randomized trial in patients hospitalized with COVID-19 showed no benefit and potentially increased harm associated with the use of convalescent plasma, with subgroup analyses suggesting that the antibody profile in donor plasma is critical in determining clinical outcomes.

Philippe Bégin, Jeannie Callum, Donald M. Arnold

Article | 15 September 2021 | Open Access

[Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis](#)

Preliminary and exploratory analyses show that a third dose of the COVID-19 vaccine mRNA-1273 or variant-modified boosters can boost levels of neutralizing antibodies against SARS-CoV-2 variants.
Angela Choi, Matthew Koch, Darin K. Edwards

Article / 29 September 2021 | Open Access

[Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection](#)

Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine ChAdOx1 nCoV-19 are identified as correlates of protection against symptomatic infection.
Shuo Feng, Daniel J. Phillips, Christopher J. Williams

Article | 03 September 2021 | Open Access

[Predictors of COVID-19 epidemics in countries of the World Health Organization African Region](#)

A new study from the WHO African Region identifies features of countries that predict timing of the first case and the per capita mortality rate for the first and second waves of the COVID-19 epidemics.
Feifei Zhang, Humphrey Karamagi, Mark E. J. Woolhouse

Nature Reviews Genetics

Volume 22 Issue 11, November 2021

<https://www.nature.com/nrg/volumes/22/issues/11>

[Reviewed earlier]

Nature Reviews Immunology

Volume 21 Issue 11, November 2021

<https://www.nature.com/nri/volumes/21/issues/11>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 20 Issue 11, November 2021

<https://www.nature.com/nrd/volumes/20/issues/11>

[Reviewed earlier]

New England Journal of Medicine

November 18, 2021 Vol. 385 No. 21

<http://www.nejm.org/toc/nejm/medical-journal>

Original Articles

[Early Convalescent Plasma for High-Risk Outpatients with Covid-19F.](#)

[K. Korley and Others](#)

Editorials

[Audio Interview: The Legal Basis for Covid-19 Restrictions and Mandates](#)

[E.J. Rubin, L.R. Baden, M.M. Mello, and S. Morrissey](#)

Pediatrics

Vol. 148, Issue 5 1 Nov 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 11, November 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-11>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 20 Nov 2021)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 20 Nov 2021)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 20 Nov 2021)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 20 Nov 2021)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 20 Nov 2021]

Research Article

[Influenza vaccination coverage among emergency department personnel is associated with perception of vaccination and side effects, vaccination availability on site and the COVID-19 pandemic](https://doi.org/10.1371/journal.pone.0260213)

Anna-Maria Stöckeler, Philipp Schuster, Markus Zimmermann, Frank Hanses

Research Article | published 19 Nov 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0260213>

[Evaluation of the United States COVID-19 vaccine allocation strategy](#)

Md Rafiul Islam, Tamer Oraby, Audrey McCombs, Mohammad Mihrab Chowdhury, Mohammad Al-Mamun, Michael G. Tyshenko, Claus Kadelka
Research Article | published 17 Nov 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0259700>

[COVID-19 vaccine uptake and hesitancy survey in Northern Ireland and Republic of Ireland: Applying the theory of planned behaviour](#)

Gavin Breslin, Martin Dempster, Emma Berry, Matthew Cavanagh, Nicola C. Armstrong
Research Article | published 17 Nov 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0259381>

[Individual determinants of COVID-19 vaccine hesitancy](#)

Philip Gerretsen, Julia Kim, Fernando Caravaggio, Lena Quilty, Marcos Sanches, Samantha Wells, Eric E. Brown, Branka Agic, Bruce G. Pollock, Ariel Graff-Guerrero
Research Article | published 17 Nov 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0258462>

[Cross-sectional study on the prevalence of influenza and pneumococcal vaccination and its association with health conditions and risk factors among hospitalized multimorbid older patients](#)

Dimitrios David Papazoglou, Oliver Baretella, Martin Feller, Cinzia Del Giovane, Elisavet Moutzouri, Drahomir Aujesky, Matthias Schwenkglens, Denis O'Mahony, Wilma Knol, Olivia Dalleur, Nicolas Rodondi, Christine Baumgartner
Research Article | published 16 Nov 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0260112>

[Can vaccination roll-out be more equitable if population risk is taken into account?](#)

David R. Sinclair, Asri Maharani, Daniel Stow, Claire E. Welsh, Fiona E. Matthews
Research Article | published 15 Nov 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0259990>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 20 Nov 2021]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

November 09, 2021; vol. 118 no. 45

<https://www.pnas.org/content/118/45>

[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 36 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>
[New issue; No digest content identified]

Preventive Medicine

Volume 152, Part 1, November 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/152/part/P1>

[Reviewed earlier]

Proceedings of the Royal Society B

24 November 2021 Volume 288 Issue 1963

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 200 Pages e1-e10, 1-124 (November 2021)

<https://www.sciencedirect.com/journal/public-health/vol/200/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 2, July 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 6, November/December 2021

<https://journals.sagepub.com/toc/phrg/136/6>

[Reviewed earlier]

Qualitative Health Research

Volume 31 Issue 13, November 2021

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 17 Issue 4, October 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 20 Nov 2021]
[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health
(RPSP/PAJPH)**

<https://www.paho.org/journal/en>

Selected Articles

19 Nov 2021

[Long-term care in Costa Rica: Lessons for Latin America based on international evidence](#)

Special report | Spanish |

19 Nov 2021

[Social distancing as protection factor against COVID-19 in a non-metropolitan area in the State of Rio Grande do Sul, Brazil](#)

Original research | Portuguese |

19 Nov 2021

[Timely initiation of HIV antiretroviral therapy in Haiti 2004–2018: a retrospective cohort study](#)

Original research | English |

19 Nov 2021

[Combined use of serologic markers and spatial analysis for epidemiological surveillance of leprosy](#)

Original research | Portuguese |

19 Nov 2021

[Communication products for COVID-19 prevention promoted by governments in Latin America and the Caribbean](#)

Original research | Spanish |

Risk Analysis

Volume 41, Issue 9 Pages: 1497-1735 September 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 20 Nov 2021]

Perspectives

[China's COVID-19 Vaccination Strategy and Its Impact on the Global Pandemic](#)

Meng Z, Shan S, Zhang R

Risk Management and Healthcare Policy 2021, 14:4649-4655

Published Date: 15 November 2021

Science

Volume 374| Issue 6570| 19 Nov 2021

<https://www.science.org/toc/science/current>

Editorial

COVID-19 vaccines for children

BY Jeffrey S. Gerber, Paul A. Offit

18 Nov 2021: 913-91

Earlier this month, the US Centers for Disease Control and Prevention (CDC) recommended Pfizer's COVID-19 messenger RNA (mRNA) vaccine for children between 5 and 11 years of age—that's 28 million children. Yet surveys show that 42 to 66% of parents of these children are reluctant or opposed to seeking this protection. Without vaccination, it is likely that almost everyone—including young children—will be infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at some point in their lives. So, the question for parents and caregivers is: Which is worse, vaccination or natural infection?

Make no mistake—COVID-19 is a childhood illness. When SARS-CoV-2 entered the United States early in 2020, children accounted for fewer than 3% of cases; today, they account for more than 25%. More than 6 million US children have been infected with SARS-CoV-2, including 2 million between the ages of 5 and 11. At the end of October 2021, about 100,000 children per week were infected. Of the tens of thousands of children who have been hospitalized, about one-third had no preexisting medical conditions, and many have required the intensive care unit. Almost 700 children have died from COVID-19, placing SARS-CoV-2 infection among the top 10 causes of death in US children. No children have died from vaccination.

Many parents are concerned that Pfizer's mRNA vaccine was not adequately tested in young children. In a study of approximately 2400 children between 5 and 11 years of age, performed when the Delta variant was the dominant strain, vaccine efficacy was 90.7% against symptomatic disease. However, Pfizer's phase 3 study in adults involved about 40,000 participants. How could the CDC be certain that the vaccine was safe in children given the small size of the study, specifically regarding the problem of myocarditis? In postauthorization studies, myocarditis occurred in approximately 5 per 1,000,000 individuals receiving mRNA COVID-19 vaccines, possibly as high as 1 per 10,000 in young men. But context is important. Vaccine-associated myocarditis has been relatively mild and self-limited—an outcome fundamentally different from the cardiac effects associated with acute COVID-19 or multisystem inflammatory syndrome, which typically involve cardiac dysfunction and require critical care. Moreover, both in Israel and the United States, the incidence of myocarditis in children 12 to 15 years of age receiving mRNA vaccines is less than that in the 16- to 25-year-old age group. And because the dose of Pfizer's mRNA is one-third that given to older adolescents, myocarditis in the younger age group will likely be even rarer.

Myocarditis is only one piece of the risk-benefit analysis. Children need to go to school, play with friends, and participate in extracurricular activities for their social and emotional development. This is their life. Since August 2021, more than 2000 schools in the US have been forced to close because of COVID-19 outbreaks, affecting more than 1 million students. The disruption of school activities has harmed children more than any detectable vaccine side effect, including worsening of mental health, widening education gaps, and decreased physical activity. These harms have disproportionately affected people of color, Indigenous persons, and individuals of lower socioeconomic status, further exacerbating inequities. Avoidance of routine health care and routine vaccination has also emerged,

with potentially devastating future consequences. Furthermore, children live closely with and rely on adults to whom they can pass SARS-CoV-2 infection—adults who can be overwhelmed by this infection. And children grow up. Countries are going to need a highly protected population for as long as COVID-19 exists in the world, which will likely be for years if not decades. Vaccinating all children against SARS-CoV-2 could be among the most impactful public health efforts the US has seen in decades. Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It's why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis—none of which, even before vaccines were available, killed as many as SARS-CoV-2 per year.

Some parents are understandably hesitant to vaccinate their young children. However, a choice not to get a vaccine is not a risk-free choice; rather, it's a choice to take a different and more serious risk. The biomedical community must strive to make this clear to the public. It could be one of the most important health decisions a parent will make.

Policy Forum

[Create a COVID-19 commission](#)

BY Christopher F. Chyba et al.

18 Nov 2021: 932-935

Conclusion

The task of a nonpartisan COVID-19 commission will be to produce a clear-eyed assessment of why and how the United States fared so poorly in this pandemic, as well as how particular successes were achieved. Where possible, it will be valuable to make this assessment in a comparative context, both with respect to previous pandemics and with respect to the experiences of other advanced-economy nations (2, 5, 6). The commission should identify how the relevant US institutions can be improved (potentially by both legislative and executive action) and better work together to ensure superior outcomes when future pandemics occur, as they surely will.

Reports

[COVID-19 transmission dynamics underlying epidemic waves in Kenya](#)

BY Samuel P. C. Brand [...] Edwine Barasa

07 Oct 2021: 989-994

Open Access

Waves of SARS-COV-2 infection in Kenya were driven by a combination of socioeconomic circumstance and emerging variants.

Science Translational Medicine

Volume 13 | Issue 620 | 17 Nov 2021

<https://www.science.org/toc/stm/current>

Focus

[An mRNA-based anti-tick vaccine catches ticks red-handed](#)

BY Petr Kopáček, Radek Šíma, Jan Perner

17 Nov 2021

An anti-tick mRNA cocktail vaccine promotes tick detachment and prevents transmission of tick-borne infection in guinea pigs (Sajid et al).

Research Articles

[mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent](#)

BY Andaleeb Sajid, [...] Erol Fikrig

17 Nov 2021

An Ixodes scapularis saliva mRNA vaccine induces tick resistance and prevents Borrelia burgdorferi infection in guinea pigs.

Social Science & Medicine

Volume 289 November 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/289/suppl/C>

Research article Abstract only

[Do cognitive styles affect vaccine hesitancy? A dual-process cognitive framework for vaccine hesitancy and the role of risk perceptions](#)

Mauro Martinelli, Giuseppe Alessandro Veltri

Article 114403

Research article Full text access

[Vaccine uptake and constrained decision making: The case of Covid-19](#)

Leonardo Becchetti, Paolo Candio, Francesco Salustri

Article 114410

Research article Full text access

[Anticipating pride or regret? Effects of anticipated affect focused persuasive messages on intention to get vaccinated against COVID-19](#)

Miriam Capasso, Daniela Caso, Mark Conner

Article 114416

Research article Abstract only

[The misunderstanding of vaccine efficacy](#)

K. Tentori, A. Passerini, B. Timberlake, S. Pighin

Article 114273

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 20 Nov 2021]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 43 September–October 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/43/suppl/C>
[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 11 Pages: i-iv, 1325-1525 November 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 39, Issue 46 Pages 6713-6812 (5 November 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/46>

Short communication Full text access

[Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon](#)

Rima Moghnieh, Rana Mekdashi, Salam El-Hassan, Dania Abdallah, ... Abdul Rahman Bizri

Pages 6713-6719

Short communication Open access

[Coverage and factors associated with receiving campaign polio vaccines in an urban population in Guinea-Bissau](#)

M. Buus, I. da Silva, S. Nielsen, S.M. Thysen, A.B. Fisker

Pages 6720-6726

Review article Abstract only

[Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines](#)

Madison C. Silver, Peter J. Neumann, Siyu Ma, David D. Kim, ... Daniel A. Ollendorf

Pages 6727-6734

Research article Open access

[A self-administered virtual reality intervention increases COVID-19 vaccination intention](#)

Aske Mottelson, Clara Vandeweerdt, Michael Atchapero, Tiffany Luong, ... Guido Makransky

Pages 6746-6753

Research article Open access

[Feasibility of age- and gestation-based routine universal influenza vaccines schedules for children aged 6 months – 2 years and pregnant women](#)

T.K.N. Sandra Dang, Romén Rivero Cabrera, Karene Hoi Ting Yeung, Ingeborg M. van der Putten, E.

Anthony S. Nelson

Pages 6754-6761

Research article Abstract only

[Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study](#)

Sanjay Kewalchand Lalwani, Padmasani Venkat Ramanan, Amita Sapru, Balasubramanian Sundaram, ...
Stephen P. Lockhart
Pages 6787-6795

Research article Abstract only

[A systems map of the economic considerations for vaccination: Application to hard-to-reach populations](#)

Sarah N. Cox, Patrick T. Wedlock, Sarah W. Pallas, Elizabeth A. Mitgang, ... Bruce Y. Lee
Pages 6796-6804

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 20 Nov 2021]

Open Access Article

[The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities](#)

by Yan Li et al.

Vaccines 2021, 9(11), 1368; <https://doi.org/10.3390/vaccines9111368> (registering DOI) - 20 Nov 2021

Abstract

This study estimates the cost-effectiveness of vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) among infants in Beijing, Shanghai, Shenzhen, Chengdu, Karamay, Qingdao, and Suzhou. Methods: A previously published cost-effectiveness model comparing vaccination with PCV13 to no vaccination was localized to the [...]

Open Access Article

[Vaccinating against COVID-19: The Correlation between Pro-Vaccination Attitudes and the Belief That Our Peers Want to Get Vaccinated](#)

by Darie Cristea et al.

Vaccines 2021, 9(11), 1366; <https://doi.org/10.3390/vaccines9111366> (registering DOI) - 20 Nov 2021

Abstract

This study verifies whether there is a strong correlation between the pro-vaccination, against COVID-19 attitude of the respondents and their belief that most of those around them want to be vaccinated against COVID-19. For this purpose, we analyzed data from a sociological survey [...]

Open Access Systematic Review

[Pharmacists' Perceived Barriers to Human Papillomavirus \(HPV\) Vaccination: A Systematic Literature Review](#)

by Oluwafemifola Oyedele et al.

Vaccines 2021, 9(11), 1360; <https://doi.org/10.3390/vaccines9111360> (registering DOI) - 19 Nov 2021

Abstract

About 45:000 cancers are linked to HPV each year in the United States alone. The HPV vaccine prevents cancer and is highly effective, yet vaccination coverage remains low. Pharmacies can play a meaningful role in increasing HPV vaccination access due to their availability [...]

Open Access Article

[Compliance Indicators of COVID-19 Prevention and Vaccines Hesitancy in Kenya: A Random-Effects Endogenous Probit Model](#)

by [Abayomi Samuel Oyekale](#)

Vaccines 2021, 9(11), 1359; <https://doi.org/10.3390/vaccines9111359> (registering DOI) - 19 Nov 2021

Abstract

Vaccine hesitancy remains a major public health concern in the effort towards addressing the COVID-19 pandemic. This study analyzed the effects of indicators of compliance with preventive practices on the willingness to take COVID-19 vaccines in Kenya. The data were from the COVID-19 [\[...\]](#)

Open Access Review

[A Review of the Implementation Status of and National Plans on HPV Vaccination in 17 Middle-Income Countries of the WHO Western Pacific Region](#)

by [Rei Haruyama et al.](#)

Vaccines 2021, 9(11), 1355; <https://doi.org/10.3390/vaccines9111355> - 18 Nov 2021

Abstract

The World Health Organization's Western Pacific Region is responsible for one-fourth of the global cervical cancer burden, and nearly 90% of that burden is concentrated in middle-income countries (MICs). Applying a conceptual model of implementation of population-based interventions, we synthesized the current implementation [\[...\]](#)

Open Access Review

[A Review of the Implementation Status of and National Plans on HPV Vaccination in 17 Middle-Income Countries of the WHO Western Pacific Region](#)

by [Rei Haruyama et al.](#)

Vaccines 2021, 9(11), 1355; <https://doi.org/10.3390/vaccines9111355> - 18 Nov 2021

Abstract

The World Health Organization's Western Pacific Region is responsible for one-fourth of the global cervical cancer burden, and nearly 90% of that burden is concentrated in middle-income countries (MICs). Applying a conceptual model of implementation of population-based interventions, we synthesized the current implementation [\[...\]](#)

Open Access Article

[Vaccine Knowledge, Awareness and Hesitancy: A Cross Sectional Survey among Parents Residing at Sandakan District, Sabah](#)

by [James Yau Hon Voo et al.](#)

Vaccines 2021, 9(11), 1348; <https://doi.org/10.3390/vaccines9111348> - 17 Nov 2021

Abstract

Incomplete childhood immunization against communicable diseases is a major concern and vaccine hesitancy remains a hurdle to overcome in primary vaccination programs. This study was to examine the parents' vaccine knowledge, awareness and hesitancy in relation to their children's immunization status. Methods: [\[..\]](#)

Value in Health

November 2021 Volume 24 Issue 11 p1543-1714

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]



Pre-Print Servers

bioRxiv

<https://www.biorxiv.org/>

bioRxiv (pronounced "bio-archive") is a free online archive and distribution service for unpublished preprints in the life sciences. It is operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution. By posting preprints on bioRxiv, authors are able to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals.

[Accessed 20 Nov 2021]

Selected Content

No new digest content identified.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 20 Nov 2021]

Software Tool Article metrics

Revised

[Route Optimization Tool \(RoOT\) for distribution of vaccines and health products](#) [version 2;

peer review: 3 approved with reservations]

Zelda B. Zabinsky, Mariam Zameer, Larissa P.G. Petroianu, Mamiza M. Muteia, Aida L. Coelho

Peer Reviewers Hua Ni; Ryan McWhorter; Andrew Inglis

Funder - Bill and Melinda Gates Foundation

LATEST VERSION PUBLISHED 15 Nov 2021

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

[Accessed 20 Nov 2021]

Selected Content

[Effects of trust, risk perception, and health behavior on COVID-19 disease burden: Evidence from a multi-state US survey](#)

Benjamin J Ridenhour, Dilshani Sarathchandra, Erich Seamon, Helen Brown, Fok-Yan Leung, Maureen Johnson-Leon, Mohamed Megheib, Craig R Miller, Jennifer Johnson-Leung

medRxiv 2021.11.17.21266481; doi: <https://doi.org/10.1101/2021.11.17.21266481>

[Uptake of Covid-19 vaccines among frontline workers in California state prisons](#)

Lea Prince, Elizabeth Long, David Studdert, David Leidner, Elizabeth T Chin, Jason R Andrews, Joshua A Salomon, Jeremy D Goldhaber-Fiebert

medRxiv 2021.11.18.21266535; doi: <https://doi.org/10.1101/2021.11.18.21266535>

[The long-term success of mandatory vaccination laws at implementing the first vaccination campaign in 19th century rural Finland](#)

Susanna Ukonaho, Virpi Lummaa, Michael Briga

medRxiv 2020.12.14.20247577; doi: <https://doi.org/10.1101/2020.12.14.20247577>

[Public opinion on global distribution of COVID-19 vaccines: evidence from two nationally representative surveys in Germany and the United States](#)

Matthias Klumpp, Ida G. Monfared, Sebastian Vollmer

medRxiv 2021.08.16.21262116; doi: <https://doi.org/10.1101/2021.08.16.21262116>

[High COVID-19 vaccine coverage allows for a re-opening of European universities](#)

Jana Lasser, Timotheus Hell, David Garcia

medRxiv 2021.11.16.21266383; doi: <https://doi.org/10.1101/2021.11.16.21266383>

[High COVID-19 vaccine coverage allows for a re-opening of European universities](#)

Jana Lasser, Timotheus Hell, David Garcia

medRxiv 2021.11.16.21266383; doi: <https://doi.org/10.1101/2021.11.16.21266383>

Wellcome Open Research [to 20 Nov 2021]

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 20 Nov 2021]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Open Letter metrics AWAITING PEER REVIEW

[Engaged genomic science produces better and fairer outcomes: an engagement framework for engaging and involving participants, patients and publics in genomics research and healthcare implementation](#) [version 1; peer review: awaiting peer review]

Madeleine J. Murtagh, Mavis Machirori, Clara L. Gaff, Mwenza T. Blell, Jantina de Vries, Megan Doerr, Edward S. Dove, Audrey Duncanson, Jillian Hastings Ward, Rachele Hendricks-Sturup, Calvin W. L. Ho, Amber Johns, Yann Joly, Kazuto Kato, Keiko Katsui, Judit Kumuthini, Fiona Maleady-Crowe, Anna Middleton, Richard Milne, Joel T. Minion, Mogomotsi Matshaba, Stephanie Mulrine, Christine Patch, Rosalyn Ryan, William Viney

Peer Reviewers Invited

Funders: Wellcome Trust; Economic and Social Research Council; H2020 European Research Council; Medical Research Council

PUBLISHED 15 Nov 2021

* * * *

[Think Tanks](#)

Brookings [to 20 Nov 2021]

<http://www.brookings.edu/>

Accessed 20 Nov 2021

Essay

[Coming together: Forging new paths to action for the Sustainable Development Goals](#)

John McArthur, Zia Khan, and Jacob Taylor

Wednesday, November 17, 2021

Center for Global Development [to 20 Nov 2021]

<http://www.cgdev.org/page/press-center>

Accessed 20 Nov 2021

[No new digest content identified]

Chatham House [to 20 Nov 2021]

<https://www.chathamhouse.org/>

Accessed 20 Nov 2021

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 20 Nov 2021

Congressional Testimony

[Vaccine Diplomacy in Latin America and the Caribbean: The Importance of U.S. Engagement](#)

November 18, 2021 | By [Daniel F. Runde](#)

Transcript

[COVAX Past, Present, and Future: A Conversation with Dr. Seth Berkley](#)

November 17, 2021

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 20 Nov 2021

November 19, 2021 *News Release*

[Analysis Examines How States Can Use Medicaid Programs to Facilitate Access to Vaccines for Low-Income Children](#)

As states expand COVID-19 vaccination efforts to reach newly eligible children ages 5 to 11, a new KFF analysis highlights several tools state Medicaid programs have at their disposal to increase access to, and take up of, vaccines among lower-income children. Among the key findings: States can request Medicaid administrative...

November 19, 2021 *News Release*

[More Than 6 in 10 of the Remaining 27.4 Million Uninsured People in the U.S. are Eligible for Subsidized ACA Marketplace Coverage, Medicaid or the Children's Health Insurance Program](#)

Recent policy attention has focused on efforts to reduce the number of uninsured people in the U.S. by expanding eligibility for coverage assistance, including enhanced premium subsidies in the Affordable Care Act (ACA) Marketplace and filling the Medicaid "coverage gap." A new KFF analysis shows that a majority of the...

November 16, 2021 *News Release*

Unvaccinated Adults are Now More Than Three Times as Likely to Lean Republican than Democratic

A new KFF COVID-19 Vaccine Monitor analysis finds that Republicans and Republican leaning independents, who represent 41% of adults, now make up 60% of the adult unvaccinated population across the country and that political partisanship is a stronger predictor of whether someone is vaccinated than any demographic factor measured. While...

ODI [Overseas Development Institute] [to 20 Nov 2021]

<https://odi.org/en/publications/>

Publications

[No new digest content identified]

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable

development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *